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DETERMINING THE ROLE PLAYED BY ARYL HYDROCARBON RECEPTOR 






by Poonam Yakkundi 
 




  Aryl hydrocarbon receptor (AHR), commonly known as an environmental sensor 
involved in the metabolism and elimination of xenobiotic substances, is also an important 
modulator in the development and functioning of the immune system. AHR expression is 
varied in the T cell subsets with the highest expression in T-helper 17 and T regulatory 
cells. Work from many researchers has suggested that AHR can act as a tumor promoter or 
a tumor suppressor depending on the tumor type. Our goal is to understand the role played 
by AHR in MC38 syngeneic colon carcinoma tumor model. In the absence of AHR, MC38 
tumor progresses by an increase in tumor associated macrophages (TAMs), M2 
macrophages and a decrease in CD8a positive cytotoxic lymphocytes. Analysis of the 
intratumoral cytokines reveals a pro-inflammatory phenotype. This has been assessed by 
pharmacologic blocking of the receptor using CH223191 and in AHR deficient (AHR-/-) 
mice. Therefore AHR acts as a tumor suppressor gene in colon carcinoma tumor model 
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CHAPTER 1: INTRODUCTION 
 
This dissertation looks into the effects of the aryl hydrocarbon receptor (AHR) on 
the infiltrating lymphocytes in the tumor environment using a MC38 (mouse colon 
carcinoma) tumor model. The introduction will provide:  
1) An overview of the AHR biology, 2) the immune system, 3) AHR and immune 
modulation, 4) an in depth review of the T cell subsets activated by AHR and 5) the 
tumor microenvironment 
 
1.1. AHR biology 
Aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor which 
resides in the cytoplasm in its latent state. It was cloned in 1976 by Poland et al. [1]. It is 
a member of the basic-helix-loop-helix (bHLH)/Per-Arnt-Sim (PAS) family of proteins. 
Toxicology and Pharmacology studies done on AHR revealed it to be an environmental 
sensor involved in the metabolism of xenobiotics like TCDD (2,3,7,8- 
Tetrachlorodibenzodioxin) and PAHs (Polycyclic Aromatic Hydrocarbons) by inducing 
CYP1A1, belonging to the cytochrome P450 family. As studies on AHR progressed, 
researchers became aware of the role it played in mediating/regulating the development 
and function of cells of the innate and adaptive immune system. The latter function of 
AHR was proposed to be mediated by its response to endogenous ligands generated by 
22 
 




important environmental sensor acting as a physiological mediator of immune cells 
(function) by providing cues from the outside.  
 
1.2. AHR gene structure 
The gene structure is composed of three functional regions –  
1. A highly conserved bHLH domain in the N terminal. This has the NLS (nuclear 
localization sequence) and NES (nuclear export sequence) which mediate the 
nucleocytoplasmic shuttling of the receptor. 
2. A degenerate Per-Arnt-Sim (PAS) domain (PAS A and PAS B). This is the dimer 
forming and ligand binding domain (amino acids 230 to 420). Structural activity 
relationship (SAR) analyses of AHR has revealed that the ligand binding pocket 
can accommodate many planar, hydrophobic compounds explaining its 
promiscuous nature [2] 
3. A poorly conserved, glutamine rich transactivation domain in the C-terminal [2].  
 
1.3 AHR ligands 
1.3.1 Exogenous ligands 
Halogenated hydrocarbons (HAHs) and polyaromatic hydrocarbons (PAHs) were 
the first groups of compounds to be identified as AHR agonists [3]. HAHs include –
dibenzo-p-dioxins, -dibenzofurans, -axo (xy) benzenes and –napthalenes, are structurally 
related AHR agonists and enter the environment as pollutants either by an industrial 
accident or by-product of waste incineration. TCDD (dioxin), one of the most potent 
24 
 
agonists known belongs to this class of compounds. PAHs, another class of AHR agonist, 
consists of 4 or more benzene rings and are by-products of combustion process found in 
chimney soot, charbroiled foods and smoke exhaust [3]. Examples of PAHs are 
benzo[a]pyrene, benzanthracene and 3-methylchloanthrene. The reactive intermediates of 
benzo[a]pyrene are known to covalently bind to macromolecules to form protein adducts 
and genotoxic DNA. The PAHs are 3 to 4 times less potent than TCDD in inducing AHR 
signaling [3]. Another class of AHR agonists are polychlorinated bi phenyls (PCBs). 
These are present in many consumables like insulators, flame retardants and adhesives. 
Due to their chemical stability and environmental pervasiveness they accumulate in the 
food chain and cause many health issues in humans and animals. These are about 100 
times less potent than TCDD in inducing AHR signaling [3]. 
 
1.3.2. Endogenous AHR ligands 
- Indigo, indirubin product of indigo plant traditionally used as a textile coloring 
dye; it has a 100 fold lower potency than TCDD [3]. 
- ITE 2-(1’4-indole-3’-carbonyl)-thiazole-4-carboxylic acid methyl ester, is isolated 
from porcine lung tissue and has approximately 100 fold lower potency than 
TCDD [3]. 
- Equilenin [3-hydroxy-1, 3, 5(10), 6, 8-estrapentaen-17-one] - This AHR agonist is 
equine estrogen. It is commonly prescribed by the name Premarin, a hormone 
replacement drug. This binds to murine AHR with approximately 1/30,000 the 
affinity of benzo[a]pyrene [3]. 
25 
 
- Arachidonic acid metabolites – Examples are lipoxin4A, prostaglandins B2, D2, 
F3α, G2, H1 and H2. 
- Heme metabolites – There are 3 heme metabolites that mediate CYP1A1 
induction, bilirubin > biliverdin > hemin in the order of their potency for AHR 
activity. 
- Tryptophan metabolites – metabolites of this amino acid like tryptamine, indole 
acetic acid (IAA), and kynurenine are endogenous AHR agonists. Photo oxidation 
of tryptophan metabolism by UV light leads to production of FICZ (6-
formylindolo [3, 2-b] carbazole). Kynurenine is produced by the breakdown of 
tryptophan by enzymes IDO (Indole 2, 3-dioxygenase) / TDO (Trp 2, 3 – 
dioxygenase). Some of the metabolites of the kynurenine pathway of tryptophan 
degradation are – N-formylkynurenine, quinolinic acid, kynurenic acid, 3-
hydroxykynurenine, 3-hydroxyanthranilic acid and NAD [4]. IDO is produced by 
some tumor cells and immune cells like DCs and macrophages. In the tumor 
milieu, increased tryptophan metabolites leads to increased AHR activation and 
increased Treg cell production [5]. Decreased tryptophan concentration leads to 
an increase in uncharged tRNA in surrounding T cells leading to the activation of 
GCN2 pathway (an amino acid sensitive stress kinase pathway). GCN2 signaling 
leads to cell cycle arrest and induces anergy in neighboring T cells [6]. Therefore, 
accumulation of kynurenine and other tryptophan metabolites leads to cell cycle 
arrest in effector T cells, creating an environment that promotes suppression and 
tolerance thereby making the tumors invisible to the immune system. Kynurenine 
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inhibited T effector cell proliferation and increased the apoptosis of T effectors 
that express increased levels of AHR [7]. 
 
1.3.3. Dietary compounds 
- Metabolites from breakdown of cruciferous vegetables like broccoli, brussel 
sprouts are AHR agonists. Examples are indole -3-carbinol (I3C) and its 
derivatives, indolo [3, 2-b] carbazole (ICZ), 3-3’-diindolylmethane (LTr-1). Some 
plant flavonoids (plant polyphenols) like chrysin, galangin, baicalein etc., are also 
AHR agonists.  
Not much is understood about how ligands of AHR activate it. Studies have shown 
that AHR has a very promiscuous ligand binding pocket because its ligands – be they 
natural (from diet), endogenous or, synthetic agonists, the prototypical HAH (dioxin) or 
PAHs have structures with physiochemical properties dramatically different from each 
other [8]. 
 
1.4. AHR signaling pathway 
AHR is a member of the basic-helix-loop-helix/Per-Arnt-Sim (bHLH/PAS) 
protein family. In the latent state it resides in the cytoplasm, is bound to actin filaments 
and forms an inactive complex with chaperone proteins p23 (PTGES3), HSP90 (heat 
shock protein, 90KDa) and AIP (AHR interacting protein) /XAP2 / ARA9 [1, 2]. AIP 
helps maintain steady state AHR levels in the cell and also prevents AHR from being 
degraded by ubiquitination [4]. AHR signaling could be either genomic or non-genomic. 
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When an exogenous or endogenous ligand binds to the receptor, there is a conformational 
change, which exposes its nuclear translocation signal and AHR translocates to the 
nucleus, forms protein-protein interactions with its partner ARNT (AHR nuclear 
translocator), in addition to co-activators and transcription factors. This complex 
regulates the transcription of specific genes [9]. AHR also acts as an E3 ubiquitin ligase 
that degrades proteins that interact with AHR such as estrogen receptor. An alternative, 
non-genomic pathway is utilized when unbound AHR helps release cSRC, which then 
phoshorylates cellular targets. The role for non-genomic AHR signaling on the immune 
response is unknown [9].  
 
The AHR + ARNT complex binds to specific promoter regions (DRE-Dioxin response 
elements) with the sequence 5’-T/G/TCGTGA/CG/TA/T-3’ on genomic DNA and 
promotes the transcription of AHR target genes. These target genes are collectively called 
the “AHR gene battery” and include the following – cyp1a1 (cytochrome P450 I family 
member a1), cyp1a2, cyp1b1, nqo1 (NAD (P) H quinone oxidoreductase 1), aldh3a1 
(aldehyde dehydrogenase 3 family, member a1), ugt1a6 (UDP glucoronosyl transferase 1 
family, polypeptide A6) and GST-Y group (glutathione S transferase). These genes 
encode phase I and II metabolizing enzymes that are responsible for the detoxification of 
xenobiotics in the liver [10]. Bradfield et al. [11] have classified AHR mediated 







1.4.1. Adaptive response pathway  
This is based on the fact that the gene is transcriptionally activated when ligand 
bound AHR binds to the DRE-containing promoter leading to the expression of gene 
products that metabolize xenobiotics (containing polycyclic aromatic structures – PAHs). 
This detoxification mechanism sometimes becomes complicated due to complex nature 
of the polycyclic compounds rendering them as more harmful electrophiles.  
 
1.4.2. Toxic response pathway 
This is the toxic response resulting from receptor mediated xenobiotic  
metabolism (PAHs and HAHs). Many AHR agonists are common environmental 
pollutants, resulting from incomplete pyrolysis of carbon sources from diesel exhaust, 
cigarette smoke, charbroiled foods, etc. Both classes of AHR agonists – PAHs and HAHs 
are toxic, but the latter are more potent due to their long half-lives leading to prolonged 
environmental persistence. 
 
1.5. AHR regulation 
AHR signaling is regulated at different levels. 1) In the cytoplasm where it is 
stored in an inactive form bound by hsp90, AIP and p23. 2) AHR is transported back to 
the cytoplasm after it has initiated the transcription of genes like cyp1a1 via the nuclear 
export sequence (NES). Once in the cytoplasm AHR is degraded by proteasomes. 3) 
AHRR (AHR repressor), a member of the bHLH-PAS family, is present in the nucleus 
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and as a result of AHR signaling migrates to the cytoplasm and negatively regulates AHR 
by competing with ARNT for heterodimer formation, which disrupts AHR-ARNT 
complex and hence AHR signaling [12]. 
 
1.6. AHR antagonists 
Antagonist is defined as a substance or chemical that interferes with or blocks the 
physiological action of a receptor (like AHR). The antagonism can be competitive or 
non-competitive. AHR antagonists are used to reverse the conditions elicited by AHR 
agonists in research mainly to understand the role played by AHR in disease like cancer 
or auto immunity (in rheumatoid arthritis (RA), MS, Crohn’s disease etc). AHR 
antagonists like GNF351, resveratrol (3, 5, 49-trihydroxystilbene) and α-napthoflavone 
have been used in RA where they reverse AHR ligand mediated effects such as – inhibit 
TCDD mediated effects such as 1) promoting IL-1β and IL-6 secretion 2) Th17 cell 
generation and 3) cyp1a1 activation. GNF351 is a high affinity AHR antagonist binding 
to the ligand binding pocket of AHR and is known to block the binding of many 
exogenous and endogenous AHR ligands. Although it is more potent than resveratrol (3, 
5, 4’-trihydroxystilbene) and α-napthoflavone [13], GNF351 shows low oral absorption 
and rapid metabolism in vivo [13]. 3’-methoxy-4-nitroflavone (MNF) and 6, 2’, 4’-
trimethoxyflavone (TMF) are two of the most potent flavonoid antagonists. MNF exhibits 
antagonistic as well as partial agonistic properties and is rapidly metabolized. TMF can 
antagonize both HAH and non-HAH agonists [14]. Some of the antagonists like flavones 
and resveratrol have exhibited high affinity for estrogen receptor [15]. CH223191 (2-
methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide) is a potent 
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and pure AHR antagonist (does not exhibit any agonist properties or affinity towards 
estrogen receptor), competitively binds to AHR and inhibits AHR-dependent 
transformation [8]. CH223191 preferentially inhibits ligand binding capacity that would 
have normally led to AHR activation and signal transduction of TCDD and related 
HAHs; but has no effect on other agonists like PAHs, flavonoids or indirubin [8]. 
CH223191 was identified by Kim et al [15], as a result of random screening of a 
chemical library purchased from Chembridge Corporation. They also showed that this 
compound successfully suppressed TCDD mediated effects (like cyp1a1 activation) both 
in vivo and in vitro. 
 
1.7. The immune system 
The immune system is the body’s defense system designed to protect the body 
from invading pathogens and at the same time having the ability to discriminate self from 
non self. The immune system is classified as innate immune system or cell mediated 
immunity and adaptive immune system or humoral immunity. The innate immunity is the 
body’s first line of defense and the adaptive one gives rise to prolonged support and 
memory a few days later upon B and T cell expansion.  
 
1.7.1. Innate immune system 
There are many chemical and biological barriers like tears, saliva, mucous, skin, 
etc. that protect organisms from pathogens. Innate immune system is triggered when 
these barriers are compromised by microbes and then recognized by pattern recognition 
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receptors (PAMPs). The responses of the innate immune system are not specific, i.e., 
exhibit generic response to all pathogens, the response is short lived and does not result in 
immune cell memory. When the physical and chemical barriers are compromised, the 
microbe/pathogen enters into the host tissue. Tissue resident phagocytes recognize the 
foreign body and immediately destroy it.  
 
Innate immune cells (white blood cells or leukocytes) originate in the bone 
marrow, some even mature here and get into circulation (either lymphatic or blood) or 
reside in the tissues. The cells of the innate immune system are innate lymphoid cells, 
mast cells, natural killer (NK) cells, phagocytes (macrophages/monocytes, granulocytes 
and dendritic cells).  
 
1.7.1.1. Granulocytes 
Granulocytes, which circulate in the blood, are further divided into neutrophils, 
basophils, eosinophils (collectively termed as polymorphonuclear leukocytes or 
granulocytes, due to the shape of their nucleus and secretion of granules in the cytoplasm, 
respectively). Mast cells are tissue resident granulocytes, defend against pathogens, and 
are important in causing allergic reactions leading to inflammation and autoimmunity. 
Basophils help combat infections, are less than 2% of all leukocytes. When injured, these 
cells secrete histamine, resulting in inflammation that helps fight infections. Eosinophils 
defend against parasites (helminths in particular) by secreting cytotoxic granules. They 
are mildly phagocytic and make up around 3% of total leukocytes. Natural killer (NK) 
cells mediate their killing action through cytotoxic granule secretion. They help body’s 
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defense by rapidly killing (in roughly 3 days) virus infected cells and also tumor cells. 
They also have the unique ability to detect stressed cells that lack surface MHC I 
expression. 
 
Neutrophils, the most important and numerous WBCs (comprise 60 to 65% of the 
total leukocytes) are the first WBCs to arrive at the site of infection or tissue damage. 
They have a long life – survive for 5 or more days in circulation and for weeks in tissues. 
They are involved in 1) phagocytosis (removal of dead and infected cells) 2) killing 
pathogens by releasing peptides and peptidases secreted by their cytoplasmic granules 3) 
wound healing by helping release cytokines and chemokines by innate and adaptive 
immune cells. The neutrophils are known to do a reverse migration into the bloodstream 
from the injury site and 4) act as antigen presenting cells (APCs) to the T cells. 
 
1.7.1.2. Neutrophils in cancer 
In the tumor microenvironment, tumor associated neutrophils (TANs) have a 
conflicting role; either promote tumor growth by invasion and angiogenesis (protumor 
N2 neutrophils) or inhibit tumor (antitumor N1 neutrophils) based on the environmental 
cues they receive [16]. TANs produce MMP9 that contributes towards angiogenesis [17]. 
In the tumor microenvironment (TME), 1) Increased levels of TANs in and around 
tumors results in poor patient prognosis (increased CXCL5 levels in human HCC 
patients) 2) neutrophils in tumors recruit many chemokines and cytokines as they would 
in acute wound responses. This could lead to increased inflammation and amount of 
chemokines (like CXCL5/CXCR2) involved in epithelial mesenchymal transition (EMT) 
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leading to tumor invasion 3) TANs in the TME are thought to act as APCs and present 
antigens to cytotoxic lymphocytes (CTLs) thereby increasing immune surveillance [16]. 
 
1.7.1.3. Dendritic cells (DCs)  
These cells were discovered by Steinman and Cohn in 1973 and they termed them 
as dendritic cells because of their dendrite (of neurons) like protrusions. They originate in 
the bone marrow, come into circulation and then undergo maturation. DCs are 
characterized by 1) expressing high levels of MHC II and CD11c 2) migrate from non-
lymphoid to lymphoid tissues in order to stimulate and prime T cells. Important subsets 
of DCs are 1) myeloid or conventional DCs (cDCs) with the expression marker CD11b. 
The cross-presenting DCs express CD103, CD8, CLEC9A, XCR1 and Langerin. The 
precursors of cDCs exit the bone marrow, migrate to secondary lymphoid and non-
lymphoid organs via blood and differentiate to cDCs. 2) plasmacytoid DCs (pDCs) – 
terminally differentiate in the bone marrow, do not express MHC II and express B220, 
Siglec-1. 3) Another set of specialized and self-renewing population of DCs are 
Langerhans cells (of stratified squamous epithelium) and microglia (parenchyma of 
brain) [18]. Immature DCs express less cell surface MHC, chemokine receptors – CCR1, 
CCR2 and CCR6 and are highly endocytic in nature. The mature DCs express more 
MHC II, co-stimulatory markers, CCR7 chemokine receptor and are less endocytic. 
Endocytic activity is a process by which DCs get rid of debris and pathogens by 
phagocytosing them, a process specifically termed as ‘macropinocytosis’ and deliver 
them to MHC II vesicles for presentation to T cells [19]. The DCs are the best antigen 
presenters of the immune system and often denoted as professional antigen presenting 
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cells (APCs). When they encounter an infection, they internalize the pathogen, break 
proteins into small peptides and present them through the major histocompatibility 
complex (MHC) molecule, the chemokine receptor expression changes, they migrate to 
lymphoid tissue rich in T cells and present the antigen and co-stimulatory molecules to 
stimulate the T cells.  
 
1.7.1.4. Mononuclear phagocytic system 
Monocytes, dendritic cells and macrophages comprise the mononuclear 
phagocyte system (MPS) [20]. Monocytes mature into macrophages, leave the circulation 
and reside in tissues. Macrophages, neutrophils and DCs have specialized receptors on 
their surface called pathogen recognition receptors (PRRs) that recognize PAMPs 
(pathogen associated molecular patterns), antigens from viruses and bacteria, mainly their 
DNA, RNA and cell membrane. An example of PRRs are toll like receptors (TLRs); 
there are 11 TLRs in humans (TLR1 through TLR 11). When the macrophages encounter 
an infection, the macrophages secrete many proteins called cytokines and chemokines. 
This initiates inflammation and leads to the recruitment of neutrophils, monocytes and 
antigen presenting cells. The latter leads to activation of adaptive immune system where 
the B and T cells get activated and recruited to the site of infection. Inflammation is an 
important response of the innate immune system to combat infection. 
 
1.7.2. Adaptive immune system 
This system is comprised of B and T lymphocytes. The B lymphocytes originate 
and mature in the bone marrow. The T lymphocytes originate in the bone marrow but 
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migrate to the thymus and mature there. These naïve lymphocytes migrate to the blood, 
circulate until they encounter an antigen to initiate maturation. When antigen binds to the 
B cells receptor (BCR), the B cells are activated, proliferate and then differentiate into a 
plasma cell. The plasma cells secrete antibodies (IgM, IgG, IgD, IgA and IgE). The 
antibody secreted by the plasma cell is specific to the antigen they have encountered. 
When the antigen specific antibodies attach to the antigen on the infected cell, the cell 
gets flagged to be destroyed via processes such as opsonization, neutralization, activation 
of complement and phagocytosis. When a dendritic cell presents an antigen to the T cell 
via its MHC molecule, the antigen binds to the T cell receptor (TCR); after receiving a 
few other activation signals, the T cell becomes activated, proliferates and differentiates 
into different T cell subsets.  
 
Three types of signals that are provided by APCs are critical for T cells. 1) The 
first signal is the activation signal provided by the engagement of TCR by the MHC I/II 
molecule presenting a processed antigen. 2) The second one is the survival signal, co-
stimulatory signal – binding of CD28 on the T cell to B7 on the same APC. This induces 
expression of IL-2 (T cell growth factor) and IL-2 receptor. 3) The final signal is one 
provided by cytokines secreted from APCs. This leads to the differentiation of the T cells, 
in particular helps the CD4 + T cells to differentiate into different T cell subsets – T 
effectors or T regulatory cells. Getting all three signals is very crucial for the survival and 
proliferation of the T cell, in its absence the T cell will go into a state of anergy. 
Depending on the cytokines they encounter, the newly activated T cell differentiates into 
cytotoxic T cell (CTLs), T helper cells or T regulatory cells. The B and T cells mount a 
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response after the innate immunity has begun to fade and this response lasts for a long 
time. Some of the T and B cells give rise to memory cells, which become activated when 
encountered with the same antigen. Apart being in circulation in the blood, the 
activated/mature B and T cells reside in lymphoid organs. There are two types of 
lymphoid organs – central or primary and peripheral or secondary lymphoid organs. The 
former consists of bone marrow and thymus; the latter of spleen, lymph node and 
mucosal tissue (of the gut, respiratory track etc.). 
 
1.8. AHR mediated effects on immune cells 
AHR has a physiological and developmental role in the growth of animals. It is 
also involved in the terminal differentiation of many immune cells. Its expression is seen 
in many tissues including liver, lungs, brain, skin, cells of the immune system and so on. 
In the cells of the innate and adaptive immune system, AHR expression is detected in 
DCs, macrophages, NK cells and intraepithelial lymphocytes (IELs). Among T cell 
subsets, the AHR gene is transcriptionally silent in naïve, Th1 and Th2 cells, but the 
expression is high in Th17, Tr1 and Treg cells. Quintana et al., have shown that AHR 
affects Treg and Th17 cell differentiation in a ligand-dependent manner -treating mice 
with TCDD led to increased Tregs population and ameliorated the autoimmune disease 
EAE. Treatment with FICZ led to increased Th17 cells and exacerbated EAE [21]. 
Treatment with ITE, an endogenous AHR ligand resulted in increased Foxp3+ Tregs, 





1.8.1. Dendritic cells 
AHR mediated activation of DCs rendered them tolerogenic. Mice that were 
treated with MOG 35-55 to induce EAE, then treated with ITE (endogenous AHR ligand) 
exhibited decreased CD86, MHC II and increased CD103 expression in splenic DCs. 
There was also low expression of pro-inflammatory cytokines like IL-6, IL1β, IL-2, IL-
23 and increased expression of anti-inflammatory cytokines like IL-10 and TGF-β. EAE 
symptoms were also ameliorated [22]. TCDD mediated AHR activation of DCs altered 
DC activation, differentiation and immunoregulatory functions but not their antigen 
presenting capacity to T cells [23]. AHR activated by TCDD also increases DC 
maturation, induces increased production of IDO and increased accumulation of NF-κB 
subunit RelB which is essential for the development and function of DCs. Indeed, RelB 
null mice are deficient in myeloid DCs. Nuclear expression of RelB is one of the 
hallmarks of DC differentiation and AHR/RelB dimerization directly correlates to their 
degree of maturation and antigen presenting capacity [24].  
 
1.8.2. Natural Killer (NK) cells 
AHR is essential for the cytolytic activity of NK cells. For example, there is 
increased tumor burden in an MHC-1 deficient RMA-S mouse tumor model in AHR -/- 
mice compared to WT. AHR is expressed in NK cells from spleen upon stimulation with 
cytokines IL-2, IL-15 or IL-12. When RMA-S tumor bearing wild type mice were treated 
with FICZ (endogenous ligand, a tryptophan derivative) there was reduced tumor burden 




1.8.3. T regulatory cells 
T regulatory cells (Tregs) can be divided into natural Tregs that are Foxp3 + 
(Forkhead box p3) and induced Tregs (iTregs) that are either Foxp3+ or Foxp3-. Also 
known as suppressor cells, they are a subset of CD4+ T cells that keep the immune 
system in check and are responsible for 1) maintaining peripheral tolerance 2) preventing 
autoimmunity and 3) reducing chronic inflammation. In the process of suppressing the 
immune system and the effector T cell proliferation, Tregs inhibit 1) antitumor immunity 
and 2) sterilizing immunity [26]. Tregs express cell surface markers CD4 and CD25 and 
the intracellular marker Foxp3. In vitro, naïve CD4+ cells in the presence of cytokines 
TGF-β and anti-CD3 + anti-CD28 stimulation give rise to Treg populations [27]. Foxp3 
is a transcription factor present in Tregs and is critical for their development, survival and 
function. Foxp3 -/- mice develop severe autoimmune-like lymphoproliferative disease, - a 
fatal autoimmune disease with hyper-responsive CD4 + T cells. These mice, termed 
scurfy mice, carry a spontaneous loss of function mutation. Humans with no functional 
Foxp3 develop an autoimmune disease termed IPEX (Immunodysfunction 
polyendocrinopathy and enteropathy, an x-linked syndrome) [26]. It has been suggested 
by Vignali et al, that Treg cells use the following mechanisms to bring about immune 
tolerance. 1) Inhibitory cytokines such as IL-35, IL-10 and TGF-β are secreted by Tregs 
and suppress T effectors either by preventing their infiltration or by reducing 
inflammation. 2) Tregs are thought to secrete Granzyme A/B to kill T effectors via 
caspases or perforin enzymes stored in the granules. 3) Metabolic suppression – whereby 
increased CD25 expression in Tregs (CD25high) allows them to consume more IL-2, 
thereby reducing IL-2 needed for the survival of T effectors.  
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4) By targeting DCs, Tregs inhibit the maturation and function of DCs via binding of 
CD80/CD86 to CTLA4 molecules which deprives effector T cells of CD28 positive co-
stimulation. Tregs induce DCs to secrete IDO which also leads to the suppression of T 
effectors. 
 
1.8.4. Tr1 cells 
These cells mature in the peripheral lymphoid organs and are very important in 
maintaining immune tolerance by keeping the immune system in check. Tr1 cells secrete 
IL-10, an anti-inflammatory cytokine that dampens the antigen presenting capacity of 
DCs and antigen-specificity of T effectors and are thus involved in suppressing tissue 
inflammation and autoimmunity. In vitro, naïve CD4+ cells can be cultured in the 
presence of cytokines TGF-β + IL-27 and anti-CD3 + anti-CD28 antibodies to give rise 
to immune suppressive IL-10 secreting Tr1 cells [27]. IL-27 is thought to induce AHR, 
upon which AHR combines with c-Maf, and the AHR + c-Maf complex transactivates Il-
10 and Il-21 promoters in Tr1 cells inducing the later to secrete IL-10 cytokine [28]. 
 
1.8.5. Cytotoxic lymphocytes (CTLs or CD8a positive cells) 
There are two types of T cell co-receptors that T cells express – CD8 positive and 
CD4 positive T cells. The CD8 + cells express the cell surface marker CD8 which is a 2 
chain glycoprotein. It exists as a heterodimer (CD8αβ) and a homodimer (CD8αα), of 
which the former is present on most T cells. MHC I binds with greater affinity to CD8 αβ 
than CD8αα. These cells are important in modulating T cell responses during cancer, 
auto-immune reactions and transplant. CD8 positive T cells constitute what are called 
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cytotoxic T lymphocytes (or CTLs). They act by releasing cytotoxins – perforin, 
granzymes and granulysin present in the granules of their cytoplasm. These enzymes 
trigger the caspase cascade, a series of cysteine proteases that induce apoptosis in the 
infected cell. Paige et al have demonstrated that AHR activation by pollutants early in life 
leads to reduced CD8 + T cell responses to a viral infection (influenza A virus) later in 
life. This was suggested to be due to DNA methylation resulting from AHR activation; 
increased methylation in the DNA encoding the CD8 gene reduced its gene expression 
following an infection [29]. 
 
1.8.6. T helper 17 (Th17) cells 
These cells express the T cell co-receptor CD4 on their cells surface (CD4 + T cells). 
These CD4 + T helper cells are pro-inflammatory in nature, they defend the host against 
extracellular pathogens by recruiting neutrophils and macrophages to the affected area. 
They are controlled by the transcription factor ROR-γT. They secrete cytokines – IL-17 
A and IL17 F. They play an important role in exacerbating autoimmune responses and 
worsen autoimmune diseases like EAE, MS, Crohn’s disease. In vitro, naïve CD4+ cells 
in the presence of cytokines (TGF-β + IL-6) and anti-CD3 + anti-CD28 stimulation give 
rise to the Th17 population [27]. In cancer they play a conflicting role – they adopt a pro 
or anti-tumorigenic role based on the stimulation (cytokines, co stimulatory molecules 
and cell-cell interactions) they encounter. When a naïve T cell is stimulated with TGF-β 
+ IL-6, it differentiates into a Th17 cell (regulatory Th17 cell) with surface expression of 
CD39 and CD73 (convert ATP to immunosuppressive adenosine) and secrete IL17 and 
IL-10. This results in uncontrolled tumor growth. When a naïve T cell is stimulated with 
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IL-1β, IL-6 and IL-23, results in an effector Th17 cell that secretes IL-17 and IFN-γ and 
less of IL-10. Such a Th17 cell promotes tumor regression [30]. 
 
1.9. The Tumor Microenvironment (TME)  
  The tumor environment is more than just an accumulation of cancer cells – it is 
very complex and can be broadly classified into cancerous or transformed cells and 
stroma. Stroma provides supportive framework to the tumor and consists of 1) 
extracellular matrix (ECM) – made up of fibrous proteins, hyaluronic acid and 
proteoglycans. It also consists of cancerous cells, proteolytic enzymes like matrix 
metalloproteinases (MMPs), a disintegrin and metallic proteinases (ADAMS). These 
proteolytic enzymes are involved in ECM remodeling, influence their growth, metastatic 
potential, differentiation as well as immune cell infiltration. 2) Fibroblasts, endothelial 
cells, pericytes, mesenchymal and immune cells 3) peptides like chemokines, cytokines, 
and enzymes. Enzymes such as IDO/TDO are secreted normally by DCs and promote the 
breakdown of the amino acid tryptophan. The metabolites of tryptophan, including 
kynurenine recruit Tregs into the tumor environment and have deleterious effects on Th1 
and CD8+ T cells and 4) metabolites secreted by cancerous cells, stromal cells. 
Fibroblasts form majority of the stromal cells and secrete chemokines and cytokines [31]. 
 
Robert Schreiber proposed “The three E’s of cancer immunoediting” where in 
tumors undergo 1) immune elimination by cancer cells 2) immune equilibrium between 
cancer and immune cells and 3) immune escape by cancer cells [32].
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Inflammation plays a major role in tumor progression, affecting tumor infiltration, 
progression all the way to metastasis. In the tumor environment, both pro-tumor and anti-
tumor signals exist. If the pro-tumor signals supersede the latter, tumor growth 
progresses. Increased expression of oncogenes like ras and myc family of genes 
contribute to TME remodeling leading to the recruitment of leucocytes, or secretion of 
chemokines and cytokines that are protumorigenic. Mutations (single mutation is 
insufficient; at least 4 are required for tumor initiation) and genomic instability also aid in 
tumor progression. 
 
The tumor environment also constitutes immune cells. In mouse tumor models, 
some tumors (MC38, mouse colon carcinoma) are heavily infiltrated by immune cells 
while others (B16F10, mouse melanoma) are not. The immune infiltrates comprise of  1) 
innate immune cells - cells of mononuclear phagocytic lineage (MPS) – TAMs (tumor 
associated macrophages), tumor DCs, monocytes - these do not present antigens, but are 
thought to be precursors to TAMs and DCs, Neutrophils, mast cells, NK cells 2) adaptive 
immune system - B and T lymphocytes. All the cells in the TME communicate with each 
other in an autocrine and or paracrine fashion and modulate tumor growth. Tumor 
progression or regression is definitely modulated and directed by the abundance and 




Tumor associated macrophages (TAMs) are most frequently found in the TME. 
These are differentiated myeloid populations with immune suppressive properties. TAMs 
block anti-tumor immunity, promote angiogenesis, reactivate EMT and aid the secretion 
of immunosuppressive cytokines IL-10 and TGF-b. They can be identified by the  cell 
surface markers CD11b and F4/80 [33]. Other cells of the innate immune system present 
in the TME are neutrophils, myeloid derived suppressor cells (MDSCs), DCs and NK 
cells. All of them except NK cells have shown to be pro-tumor or anti-tumor. NK cells 
have always proved to be anti-tumor, killing tumor cells by their cytolytic activity. The 
macrophages can be of two phenotypes M1 and M2. The former is an immune promoter, 
with an anti-tumor phenotype and the latter is an immune suppressor with pro-tumor 
phenotype. The cells of the adaptive immune system constitute the CD4+ positive and 
CD8 + T cells. CD4+Foxp3+Tregs are pro-tumor and suppress anti-tumor immune 
responses. Other CD4 + T cells  like Th17, Th1, Th2, and CD8+ T cells, which are 
traditionally promoters of immunity and protect the host in case of viral or pathogen 
invasion, can switch roles and become either tumor promoters or suppressors [34]. 
 
Immune and stromal cells, like fibroblasts and endothelial cells of the TME 
secrete many cytokines and chemokines that either promote or regress the tumor 
progression. These proteins help regulate cell activation, differentiation, survival and 
trafficking of immune cells into and out of the tumor. Depending on the cytokines 
secreted by the tumor, could lead to either anti-tumor or pro-tumor environment in the 
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TME. There is enough evidence to support the fact that excessive amounts of anti-
inflammatory cytokines in the TME leads to increased malignancy. This is dependent on 
their receptor expression, relative concentrations and the activation state of the cells. [35]. 
Macrophages secrete high levels of cytokines and chemokines in the TME. M1 
macrophages produce IFN-γ and pro-inflammatory cytokines such as IL-6, IL-12, IL-23 
and TNF-α while M2 macrophages secrete inhibitory IL-10 and TGF-β. Oncoproteins 
like Ras, Myc etc., when upregulated, aid the stimulation of pro-inflammatory cytokines 
and chemokine pathways leading to increased secretion of IL-6, IL-8, IL-1β, CCL2 and 
CCL20. A chronic pro-inflammatory environment can result in the production of free 
radicals that could potentially lead to DNA damage and eventually mutations leading to 
tumor initiation/progression. IL-12 is a cytokine that is involved in the differentiation of 
Th1 cells. The p40 subunit of IL-12 is involved in the IFN-γ production and activation of 
anti-tumor immunity. MDSCs produce arginase 1 and IDO which suppress anti-tumor 
immunity by indirectly interfering with T cell activation. Various pro-angiogenic genes 
get activated, secrete VEGF, IL-8, HIF-1α, which promote angiogenesis that could lead 
to tumor progression [34].  
 
AHR acts as either a tumor promoter or suppressor depending on the tumor 
type. Its role in epithelial-mesenchymal transition and progression is also controversial. 
When looked into tumor vs. normal tissues for multiple tumors, differential AHR 
expression was seen; it can be considered either a negative or positive prognostic factor 
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[36]. The reason for the dual role of AHR in cancer is not known. Some of AHR agonists 
like TCDD are known carcinogens. Kynurenine, an endogenous ligand, produced from 
IDO-mediated tryptophan metabolism, indirectly leads to cancer progression by 
increasing Tregs and suppressing T effectors. Ligands like β-napthoflavone, I3C (from 
cruciferous vegetables) and its dimer DIM exhibit promising anti-tumor activities. The 
role of others like FICZ are not known. There is evidence for unknown endogenous 
ligands that prevent cancer. For example, AHR prevents liver carcinogenesis [37], colon 
cancer [38] and ovarian cancer [39]. In lung cancer, increased AHR expression decreased 
autophagy and inhibited migration of lung cancer cell lines [40]. In certain cancers AHR 
signaling promotes them, as seen in the case of gliomas [41] and breast cancer [42]. 
 
Mice models are used in research as there is roughly 99% similarity with humans 
in terms of pathology and physiology; there is homology in the nervous, skeletal, 
cardiovascular, immune systems etc. Although mouse models do not fully recapitulate 
the characteristics of human cancers in terms of interactions within the tumor 
microenvironment, between tumor- host and responses towards drugs and drug 
resistance, they are still a very good and affordable tool to study mechanistic pathways 
concerning basic research and drug development [50].  
 
Many mouse models are used in research and they come with their own sets of 
benefits and limitations [50].  
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1) GEMM (genetically engineered mouse model): These are derived by inducing genetic 
mutations through CRISPR/Cas or TALENs approaches. They are expensive, time 
consuming, have off target effects and could harbor lethal mutations.  
2) PDX /CDX (patient derived xenografts or cell derived xenografts): These are derived 
by implantation of human cells/tissues from either patients or cell lines into immuno-
compromised mice. These models are quick and easy to generate. Although, some of the 
drawbacks are the lack of a durable graft immune system and graft-mediated effects on 
the host.  
3) Humanized mouse models: These mice are manipulated such that mouse genes are 
knocked out and replaced by human genes so as to make human proteins. For example, 
replacement of the mouse immune system genes by human genes. These models are very 
complex, expensive and time consuming to generate.  
4) Syngeneic mouse models - These models are mostly used in cancer research; the 
transplant is histocompatable with the host and injected in immunocompetant mice, with 
an intact immune system. The transplants are often cell lines that were generated from 
mice with tumors induced by cancer promoting chemicals. These are either sub-
cutaneously implanted on the flank to obtain a palpable and visible tumor or injected 
systemically (intravenously) to study metastases. These models are very useful in 
understanding the role of immune system in cancer modulation and immune-based 
therapies [51]. Some of the commonly used syngeneic tumor models in cancer research 
are CT26 (colon carcinoma; BALB/c mice), MC38 (colon carcinoma; C57BL/6 mice), 
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B16F10 (mouse melanoma; C57BL/6 mice), 4T1 (breast cancer model using BALB/c). 
Immunotherapy based on blocking immune checkpoint inhibitors like CTLA4 (cytotoxic 
T lymphocyte associated protein 4) and PD-1 (programed death 1) for the treatment of 
cancers like metastatic melanoma, renal cell carcinoma etc. (by Bristol-Myers Squibb/ 
Medarex), were supported from data from mouse tumor models, namely – MC38, 
B16F10 and CT26. Immunotherapy utilizes the potential of the immune system to 
recognize and abrogate tumors by limiting inhibitory interactions that reduce antitumor 
responses. 
 
Based on the dual role of AHR in cancer, I sought to understand the role it plays 
in a MC38 mouse colon carcinoma model and B16F10 (mouse melanoma model). 
Changes in tumor burden after pharmacologically activating the receptor using TCDD, 
pharmacologically blocking the receptor using antagonist CH223191 and in AHR – 
deficient (AHR-/-) mice were determined. The tumor microenvironment was investigated 
in TILs along with cytokine and chemokine profiling to determine if they contribute to 
changes in tumor burden. 
 
I propose that, AHR activation by TCDD, results in increased Tregs and 






T regulatory cells suppress anti-tumor immunity by inhibiting cytotoxic T 
lymphocytes (CD8 + T cells). Activation of the AHR by agonists increases the 
differentiation of naïve T cells into T regulatory cells. Therefore, activation of AHR in 
tumor bearing mice should increase the tumor burden. 
 
Hypothesis 2 


















CHAPTER 2: MATERIALS AND METHODS 
Tumor study design  
2.1. MC38 tumor study 
The MC38 cells that were ready to be implanted were kept on ice until the 
implant was completed. The cells were implanted within 10 minutes of their harvest. On 
day 0, 25 gauge sterile needle (from Becton Dickenson) was fitted to a sterile 1ml syringe 
(BD Luer-Lok, from Becton Dickenson), then filled with 2X106 cells in 200 µl volume of 
1X PBS and implanted subcutaneously on the right flank of the mouse. This procedure 
was done in a bio-safety cabinet. While implanting the cells subcutaneously, a clearly 
visible bleb should be seen, if not the tumor growth may not be visible, may result in a 
delayed growth or no growth at all. A palpable tumor was seen on day 7 after implant. On 
day 7 after the implants, the weight of the mouse and tumor burden were recorded using a 
database called Studylog (from Studylog Systems Inc.). The height, width and length of 
the tumors were measured using a caliper and the tumor burden was calculated using the 
formula L x W x H /2. The mice were randomized based on the tumor burden and divided 
into the control (vehicle/DMSO in corn oil) and the treatment group (agonist – TCDD or 
antagonist –CH223191) such that both groups had the same average tumor burden. 
TCDD was mixed with corn oil and administered in mice at a concentration of 
1µg/mouse and depending on the experiment, was administered either once or three times 
per study. AHR antagonist CH223191 was dissolved in DMSO and administered every 
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day at 10mg/kg body weight (200 µL volume) per mouse. The drug was administered 
orally starting on day 7 till the end of the study. The tumor study involving AHR WT and 
AHR KO mice did not receive any treatment.  
Body weight and tumor burden were monitored on days 7, 10, 14, 17, 20 and 23. 
The study ended on day 26 or sooner if the study endpoint was reached. Mice were 
sacrificed if they exhibited significant weight loss (>20%), have a tumor volume which is 
at or near the maximum allowed (2000mm3 or 10% of the body weight), the tumors were 
ulcerated or the mice are in poor health (lethargic, moribund, failure to thrive, inability to 
drink or access food, posture, vocalization and tented skin). The health of the mice and 
husbandry was monitored on a daily basis as per the guidelines of Bristol-Myers Squibb 
animal facility.  After the tumor study was completed, the mice were euthanized using 
CO2.  
For the immuno-phenotyping experiment, on day 17 after tumor implants, the tumors 
were excised from the mouse and stored in 50 mL conical tubes containing 5 mL of 
MC38 cell culture media. The tumor draining lymph nodes comprising of the axillary, 
brachial and inguinal lymph nodes on the tumor bearing side were harvested in a 24 well 
cell culture plate containing 1.5 mL of MC38 cell culture media. These procedures were 
performed in a bio-safety cabinet and the harvested tissues were kept on ice.  
 
2.2. B16F10 tumor study 
The B16F10 cells that were ready to be implanted were kept on ice until the 
implant was completed. The cells were implanted within 10 minutes of their harvest. On 
day 0, 25 gauge sterile needle (from Becton Dickenson) was fitted to a sterile 1ml syringe 
51 
 
(BD Luer-Lok, from Becton Dickenson), then filled with 1X106 cells in 200ul volume 
and implanted subcutaneously on the right flank of the mouse. This procedure was done 
in a bio-safety cabinet. On day 7 after the implants, the weight of the mouse and tumor 
burden were recorded using a database called Studylog (from Studylog Systems Inc.). 
The height, width and length of the tumors were measured using a caliper and the tumor 
burden was calculated using the formula L x W x H /2. The mice were randomized based 
on the tumor burden and divided into the control (vehicle/DMSO) and the treatment 
group such that both groups had the same average tumor burden. AHR antagonist 
CH223191 was dissolved in DMSO and administered every day at 10mg/kg body weight 
per mouse. The drug was administered orally starting on day 7 till the end of the study.  
The tumor study involving AHR WT and AHR KO mice did not receive any 
treatment. Body weight and tumor burden were monitored on days 7, 10, 14, 17, 20 and 
23. The study ended on day 26 or sooner if the study endpoint was reached. Mice were 
sacrificed if they exhibited significant weight loss (>20%), have a tumor volume which is 
at or near the maximum allowed (2000mm3 or 10% of the body weight), the tumors were 
ulcerated or the mice are in poor health (lethargic, moribund, failure to thrive, inability to 
drink or access food, posture, vocalization and tented skin). The health of the mice and 
husbandry was monitored on a daily basis as per the guidelines of Bristol-Myers Squibb 








For all tumor burden studies, the C57BL/6 mice, with wild type AHR gene, were 
purchased from The Jackson Laboratories. These mice underwent a 3 week quarantine 
and acclimatization period in the Bristol-Myers Squibb Company Animal facility after 
which they were transferred to the protocol room. The mice used on the study were 
female and 8 weeks of age at the time of tumor implants.  
For the studies involving AHR WT and AHR KO (-/-) mice,  the AHR WT and 
KO were obtained from matings of male and female AHR heterozygous (+/-) mice (were 
littermates) that were purchased from The Jackson Laboratories. Some of WT and KO 
mice were also obtained from AHR (-/-) X AHR (-/-) and AHR (+/+) X AHR (+/+) 
matings respectively. The KO mice from both sets of mating did not exhibit any 
differences in their tumor burden. These mice were housed and bred at the Bristol-Myers 
Squibb Animal facility. Female mice between 8 to 12 weeks of age at the time of tumor 
implants were used in the study. All mice WT and KO that were put on a tumor study had 
an acclimatization period of 5 days in the protocol room. 
 
2.4. MC38 cell culture (for tumor study) 
The cells are grown in Corning cellgro RPMI 1640 medium, 1X with L-glutamine 
(Thermo Fisher) supplemented with heat inactivated 10% fetal bovine serum – FBS 
(from Gibco, Thermo Fisher) in a  5% CO2 incubator at 37°C. The cells were passaged 
three times a week. Heat inactivated FBS was obtained by heating for 30 minutes at 56°C. 
The FBS consists of a lot of nutrients including complement. Heat inactivation denatures 
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the complement proteins as these proteins could affect immunological studies by 
interfering with the host’s immune response. For tumor implants the cells were split into 
half one day before. The cells were counted using Vi-CELL XR (from Beckman 
Coulter), washed once with 1X PBS (from Corning cellgro cell culture Phosphate 
Buffered Saline, 1X, without calcium and magnesium) and re-suspended in 1X PBS at a 
concentration of 2X106 cells in  200ul of 1X PBS. The cells were in culture for not more 
than a month after which a new thaw of cells were used. 
 
2.5. B16F10 cell culture (for tumor study)                                                                                            
The cells were obtained from a frozen cell bank located at Bristol Myers Squibb in 
Redwood City. They were grown in Corning 1X DMEM with L-glutamine, 4.5g/L 
glucose and sodium pyruvate (Fisher Scientific) with 10% heat inactivated FBS (from 
Gibco, Thermo Fisher) in a  5% CO2 incubator at 37°C. The cells were passaged three 
times a week. For tumor implants the cells were split into half one day before. The cells 
were counted using Vi-CELL XR (from Beckman Coulter), washed once with 1X PBS 
(from Corning cellgro cell culture Phosphate Buffered Saline, 1X, without calcium and 
magnesium) and re-suspended in 1X PBS at a concentration of 1X106 cells in  200ul of 
1X PBS. The cells were in culture for not more than a month after which a new thaw of 






2.6. Preparing TCDD for intra-peritoneal administration in mice 
TCDD dissolved in DMSO (at 50µg/mL concentration) was purchased from 
Cambridge Isotope Laboratories. This was mixed with corn oil - NF grade (CO136-
25ML), purchased from Spectrum Chemicals. The mixture was loaded into sterile 1mL 
syringes (BD Luer-Lok, from Becton Dickenson) and 1µg/mouse was injected intra-
peritoneally in mice using a 20 gauge sterile needle (from Becton Dickenson). The 
administration was done on day -1, a day prior to MC38 tumor implant. 
 
2.7. Preparing AHR antagonist to be administered orally in mice  
CH223191 (C8124-5MG) and DMSO (Dimethyl Sulfoxide-HybriMax, sterile 
filtered, D2650) were both purchased from Sigma-Aldrich. Corn oil, NF grade (CO136-
25ML) was purchased from Spectrum Chemicals. CH223191 was stored in 4°C as per 
manufacturer’s instructions. The oil was stored at room temperature, but once open was 
stored at 4°C. The preparation that was administered to the mice was prepared in a Bio-
Safety cabinet and kept sterile at all times. The mixture was fed to the mice using sterile 
feeding needles – disposable AFN 20G plastic animal feeding needles (from Cadence 
Science). CH223191 was dissolved in DMSO, under sterile conditions to obtain a 
concentration of 25 mg/mL. This working stock was dissolved in corn oil to obtain a 






2.8. AHR KO mice breeding 
The mice were bred at Bristol-Myers Squibb Company Animal facility in 
Redwood City, CA. The tails (2 mm in size) were clipped at the time of weaning on day 
21 after birth for genotyping. 
 
2.9. Genotyping protocol to distinguish between AHR WT and KO mice 
The genotyping protocol was obtained from The Jackson Laboratories. The DNA 
was extracted from mouse tail snips using Extract N Amp tissue DNA extraction kit from 
Sigma.  
 
2.9.1. DNA extraction protocol 
4 parts of extraction buffer was mixed with 1 part of tissue extraction solution. 
100ul of this solution was added to the tails, so that the tail clips were immersed in the 
buffer. The tails were incubated at room temperature for 10 minutes. Then incubated at 
95°C heat block for 10 minutes. 100ul of neutralization buffer was added and the crude 
DNA was transferred to a fresh box – DNA box. The DNA was then stored at 4°C until 
used for PCR set up. 
 
2.9.2. PCR set up 
The PCR was set up using PCR buffer from Sigma. 1X concentration of this buffer was 
mixed with forward and reverse PCR primers (to obtain a final concentration of 10uM). 
The PCR primers were purchased from Life Technologies (Thermo Fisher).  




                       





 Table2: Genotyping primer sequences for identifying homozygous AHR KO (-/-), 




                     





Below is a picture of the PCR amplicons run on a 3% agarose gel (with ethidium 
bromide from Bio-Rad) for 14 minutes at 165 Volts. The gel was imaged using 
AlphaImager (from Protein Simple). The mutant band size is 450bp and the wild type 
band size is 669bp. Samples that showed one mutant band of 450bp were identified as 
homozygous KO, one wild type band of 669bp as homozygous for wild type and two 
bands – mutant (450bp) and WT (669 bp) were identified as heterozygous mice. Sample 






Figure 1: 3% agarose gel depicting amplicons after PCR run to identify homozygous 









2.10.1. MC38 cell culture  
The cells were obtained from a frozen cell bank located at Bristol Myers Squibb 
in Redwood City. The cells were grown in Corning cellgro RPMI 1640 medium, 1X with 
L-glutamine (Thermo Fisher) with 10% fetal bovine serum (FBS) (from Gibco, Thermo 
Fisher) in a 5% CO2 incubator at 37°C. FBS was heat inactivated by heating for 30 
minutes at 56°C. The FBS consists of a lot of nutrients including complement. Heat 
inactivation kills the complement proteins as these proteins could affect immunological 
studies by interfering with the host’s immune response. The cells were grown to reach 
90% confluence and were split three times a week. The cells were in culture for not more 
than a month after which a new thaw of cells were cultured. 
 
2.10.2. B16F10 cell culture  
The cells were obtained from a frozen cell bank located at Bristol Myers Squibb 
in Redwood City. They were grown in Corning 1X DMEM with L-glutamine, 4.5g/L 
glucose and sodium pyruvate (Fisher Scientific) with 10% heat inactivated FBS in a  5% 
CO2 incubator at 37°C and split three times a week. The cells were in culture for not 
more than a month after which a new thaw of cells were cultured. 
 
2.10.3. Hepa1c1c7 cell culture  
A frozen aliquot of these cells were obtained from Dr. William Chan’s lab 
(University of the Pacific). They were grown in alpha minimum essential medium 




2.10.4. RT-PCR  
  For the gene expression experiment, the cells were counted using Vi-CELL XR 
(Beckman Coulter) and plated in a 6 well plate at 1X106 cells and incubated overnight in 
a 5% CO2 incubator at 37°C. TCDD dissolved in DMSO at a concentration of 1nM per 
well or equivalent volume of DMSO was added per well, with a n=3 per condition. The 
cells were incubated in a 5% CO2 incubator at 37°C. After 3, 6, 18 and 24 hours of 
incubation they were was with 1XPBS, harvested in Trizol (Zymo Research), were flash 
frozen on dry ice and stored in -80 deg C freezer until RNA extraction. 
RNA was extracted using Direct-zol Total RNA extraction kit (Zymo Research) 
by following the instructions provided by the manufacturer. RNA quantitation was done 
using a QIAxpert  (Qiagen). 1µg of RNA per reaction was used to set up the cDNA 
reaction. cDNA was prepared immediately from RNA using the SuperScript III first 
strand synthesis super mix for qRT-PCR (Thermo Fisher Scientific) following 
manufacturer’s instructions. The prepared cDNA was immediately used to set up the RT-
PCR reaction. 2 µL of cDNA was used per sample to set the RT-PCR reaction with three 
technical replicates. Real time PCR was done using Sso advanced SYBR green master 
mix from Bio-Rad. The samples were run on the LC480 cycler from Roche. GAPDH was 
used as the reference gene. All the primers for the assay were ordered from IDT 
(Integrated DNA Technologies). The assay was set up in a 384 well plate. Below is an 




      Table 4: RT-PCR assay – 384 well plate set up, PCR set up protocol and PCR cycling      





2.10.5. PCR primers 
          
  Gene  Forward Primer Reverse Primer   
  Ahr GCCCTTCCCGCAAGATGTTAT CAGGGGTGGACTTTAATGCAA   
  cyp1a1 CAATGAGTTTGGGGAGGTTACTG CCCTTCTCAAATGTCCTGTAGTG   
  ugt1a GCTTCTTCCGTACCTTCTGTTG GCTGCTGAATAACTCCAAGCAT   
  nqo AGGATGGGAGGTACTCGAATC TGCTAGAGATGACTCGGAAGG   
  ahrr ACATACGCCGGTAGGAAGAGA GGTCCAGCTCTGTATTGAGGC  
  cyp1a2 AGTACATCTCCTTAGCCCCAG GGTCCGGGTGGATTCTTCAG   
  cyp1b1 CACCAGCCTTAGTGCAGACAG GAGGACCACGGTTTCCGTTG   
  gapdh TCTCCCTCACAATTTCCATCCCAG GGGTGCAGCGAACTTTATTGATGG   
         
Table 5: Forward and reverse primer sequences used for AHR gene battery expression  
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2.11. RT-PCR from liver samples  
 Upon termination of the study, mice were euthanized using CO2. The 
livers were harvested in RNA later (from Ambion, Thermo Fisher Scientific), stored at 
4°C until total RNA was extracted from them. Prior to RNA extraction, the tissue was 
ground in Trizol (from Zymo Research) in M-tubes (from Miltenyi Biotech) using 
GentleMacsTM (a tissue grinder from Miltenyi Biotech). Total RNA was extracted using 
the kit Direct-zol Total RNA extraction kit (Zymo Research) by following the 
instructions provided by the manufacturer. RNA quantitation was done using QIAxpert  
(from Qiagen). 2.5 µg of RNA per reaction was used to set up the cDNA reaction. cDNA 
was prepared immediately from RNA preparation using the SuperScript III first strand 
synthesis super mix for qRT-PCR (Thermo Fisher Scientific) following manufacturer’s 
instructions. Real time PCR was set up using SYBR chemistry (Sso Advanced Universal 
SYBR Green Supermix from Bio-Rad) and PCR oligos from Thermo Fisher Scientific. 
For each time point there were three mice and three technical replicates per mouse. The 
samples were run on the LC480 cycler from Roche. GAPDH diluted at a ratio of 1:500 
was used as the reference gene. The primer sequences, PCR cycling parameters and RT-
PCR assay set up are outlined in table 4. The RT-PCR data was obtained by calculating 
ΔCt (Ct of target gene-Ct of reference gene), ΔΔCt (ΔCt of target gene-ΔCt of control 







2.12. LPS administration and ELISPOT assay 
ELISPOT assay 
 The principle of ELISPOT assay is very similar to that of a sandwich 
ELISA (Enzyme-linked immunosorbant assay) technique. The assay is both qualitative 
and quantitative, and is used to determine the number of antibody or cytokine cells. The 
monoclonal or polyclonal antibodies of interest are pre-coated to the microplate, on to 
which the stimulated cells are added. The binding occurs in a humdified chamber at 37°C 
for a specified amount of time (should be determined). The cells are washed and the 
antibody/cytokine producing cells are determined using a biotinylated ab/ AP-
strepatvidin conjugate/substrate solution. The blue-black spots that are formed 
correspond to the antibody or cytokine localization and can be counted with an automated 
ELISPOT reader. 
 Lipopolysaccharide (LPS) was purchased from Sigma Aldrich and was 
dissolved in 1XPBS (from Corning cellgro cell culture Phosphate Buffered Saline, 1X, 
without calcium and magnesium) to obtain a stock of 5 mg/mL. TCDD dissolved in 
DMSO (50 µg/mL) was from Cambridge Isotope Laboratories. Mice used for the 
experiment were C57BL/6 purchased from The Jackson Laboratories. Murine IgM 
ELISPOT (Immunospot) kit for detecting IgM producing plasma cells was from CTL 
(Cellular Technology Limited). DMSO Dimethyl Sulfoxide-HybriMax, sterile filtered 
(D2650) was from Sigma-Aldrich. Corn oil, NF grade (CO136-25ML) was purchased 
from Spectrum Chemicals. 
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Some preliminary experiments were done using the IgM ELISPOT kit to obtain 
optimum cell seeding density and incubation time (of cells with capture Ig). Spleens were 
harvested from an un-stimulated mouse. Splenocytes were obtained using gentleMACSTM 
tissue dissociator (from Miltenyi Biotech) in C-tubes (for tissue grinding, from Miltenyi 
Biotech). The cells were counted using Vi-CELL XR (from Beckman Coulter). This was 
compared to the stimulated splenocytes (as they secrete more IgM than unstimulated 
ones. Stimulation was done by treating splenocytes with B-Poly S (provided with the 
ELISPOT assay kit) for 3 days in a 5% CO2 incubator at 37º C. Before plating, the cells 
were washed 3 times with CTL media, to remove any IgM present on the cell surface. 
Both stimulated and un-stimulated splenocytes were plated at the density listed below in 
table 6 on the ELISPOT plate. The latter had been coated with capture Ig the previous 
night. The plates were incubated for either 12 or 20 hours in a 5% CO2 incubator at 37º 
C. Next day the plate was washed and ELISPOT protocol was conducted as per 





   
    





                                         





2.13. ELISPOT assay on mice treated with LPS and TCDD 
 
C57BL/6 mice were injected with 1µg per mouse of TCDD dissolved in corn oil. 
DMSO dissolved in corn oil was used as the vehicle. LPS was administered at a 
concentration of 25 µg per mouse [15]. Before LPS was administered to mice on the 
No stimulation cell count B-cell stimulation cell count











study, a pilot run was conducted to see if LPS administration caused any adverse effects 
in mice. The mice (n=3 per group) were treated with 25 µg or 35 µg LPS or 1X PBS and 
monitored for 30 minutes. The spleens were harvested and IgM secreting plasma cells 
were looked into. 
TCDD (1µg /mouse) or DMSO in corn oil was administered on day -4. 25 µg of 
LPS was administered on day 0. Administration of LPS was considered as day 0. Three 
days later spleens were harvested, splenocytes obtained using gentleMACSTM and plated 
on Murine IgM ELISPOT assay plate that was coated the previous night with capture Ig. 
The cell dilutions used for plating were 62,500, 31,250, 15,625 and 7,812.5 cells per well. 
The cell dilution of 15,625 per well was used for calculating the spots which are IgM 
secreting plasma cells. There were 4 treatment groups – LPS alone, LPS + TCDD, TCDD 
alone, DMSO alone and untreated group. The assay had an n=5 in all treatment groups 
and an n=3 in the untreated group. The assay plate was incubated for 12 hours in a 5% 
CO2 incubator at 37degC. Next day the plate was washed and ELISPOT protocol was 
conducted as per manufacturer’s instructions. The plate was read in Immunospot 
analyzer. 
 
2.14. Analysis of CD138+ plasma cells by FACS 
The spleens from mice with the following treatment groups were harvested – LPS 
alone, LPS + TCDD, DMSO + LPS and untreated. The splenocytes were obtained by 
grinding the tissues in C-tubes using gentleMACS. Red blood cells from the ground 
spleens were lysed using 1X RBC lysis buffer (from Sigma Aldrich). The cells were 
counted using Vi-CELL XR (from Beckman Coulter). The cells were plated in a U-
66 
 
bottom 96 well plate (from Corning), washed once with FACS buffer (1X PBS + 2% 
FBS) and blocked using Fc block (2.4 G2, anti-mouse CD16/CD32 from Bio X Cell) at a 
concentration of 1:1000 for at least 5 minutes. The cells were then stained with 100ul of 




Table 7: List of fluorescent antibodies for identifying CD138+ plasma cells. The cells 
were stained and fixed as per the FACS protocol. The samples were run on FACS Canto 




The cells were stained for 30 minutes at 4°C in the dark. The cells were washed 
twice with FACS buffer, resuspended in 300ul of FACS buffer and analyzed by FACS on 
BD Canto from BD Biosciences. Proper compensation controls were prepared using 
splenocytes to set the PMT voltages on the FACS machine. The data was analyzed using 
FlowJo software. 
 
2.15. Flow cytometry for TILs and tumor draining lymph nodes 
The tumors and tumor draining lymph nodes were harvested on day 17 after 
tumor implants, for immuno-phenotyping. Mice were euthanized using CO2 and the 
tumors were excised and stored in 50 mL conical tubes containing 5mL of MC38 cell 
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culture media. The tumor draining lymph nodes comprising of the axillary, brachial and 
inguinal lymph nodes on the tumor bearing side were harvested in a 24 well cell culture 
plate containing 1.5 ml of MC38 cell culture media. These procedures were performed in 
a bio-safety cabinet and the tissues were kept on ice as they were being harvested. The 
tumors were weighed on a balance, weight recorded and roughly 0.3 to 0.4 g of tumor 
tissue was used for immunophenotyping studies. The remaining tissue was flash frozen 
on dry ice and stored at -80°C for future use.  
 
2.16. Tumor and lymph node digestion 
Tumors and lymph nodes were digested with enzymes – Dnase I (Sigma Aldrich) 
and Collagenase IV (from Worthington) using the digest buffer to help release the 
dendritic cells and other myeloid cells from fibroblasts. 
The weighed tumors were transferred to a gentleMACSTM C-tube (from Miltenyi 
Biotech) with 1.5ml of digest buffer (1.5ml for 0.5g of tissue). Below is the recipe for 
preparing digest buffer. All the contents of the digest buffer except for the enzymes were 





Collagenase IV was purchased from Worthington Biochemical (CLS-4), Dnase I 
from Sigma Aldrich, HBSS – Hank’s balanced salt solution from Thermo Fisher and FBS 
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from Gibco, Thermo Fisher. Tumor tissue was chopped 20 to 30 times with a pair of 
scissors to little chunks. The tubes were placed in gentleMACSTM tissue grinder (protocol 
used: m_tumor_imp_03) to grind the tumors. The samples in C-tubes were incubated at 
37°C incubator for 30 minutes with constant shaking. Tubes were then vortexed on high 
for 5 seconds. For lymph nodes digestion, the lymph node capsule was torn using a pair 
of scissors, then crushed with the flat end of a sterile syringe and pipetted with 500 µl of 
digestion buffer to tease out all the lymphocytes. These were incubated at 37°C for only 
15 minutes and then quenched with the quench buffer. The tumors and lymph nodes were 
treated in a similar fashion. The digestion enzymes were quenched with serum and EDTA 
containing media by adding 7mL of cold quench buffer. The quench buffer was made of 
Corning cellgro RPMI 1640 medium, 1X with L-glutamine (Thermo Fisher) with 10% 
fetal bovine serum (FBS) (from Gibco, Thermo Fisher) + 2mM EDTA from Corning 
cellgro. From here onwards all steps were performed on ice to maintain the integrity of 
the leucocytes. The cells were passed through a 100uM filter (Falcon cell strainer, 100uM 
pore size, from Fisher Scientific) to remove debris and hair. A small aliquot of cells 
(around 500ul) was taken for counting on a cell counter (ViCell from Beckman Coulter). 
In the meantime, cells were spun at 400g for 5 minutes at 4°C and washed once with 1X 
PBS. 1 million cells were taken per well per sample for live dead and other antibody 
staining. The cells were plated in a 96 well U-bottom plate for the convenience of 
staining, fixing and running samples in HTS mode on the BD Fortessa. Zombie aqua 
(from Biolegend) at a concentration of 1:1000 was used as the live dead stain. Zombie 
aqua is a fixable, viability dye that is amine-reactive. Therefore the cells had to be 
washed thoroughly with 1X PBS to remove all proteins. The samples were incubated 
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with 100ul of the stain for 30 minutes in the dark at 4°C. The staining was stopped by the 
addition of Fc block buffer, which also block Fc receptors that are highly expressed in 
tumors. The recipe for Fc block buffer is FACS buffer (1X PBS + 2% FBS + 2mM 
EDTA) along with 4% rat serum (from Jackson Immunoresearch) and 1:250 mouse FcX 
(Trustain fcX, anti-mouse CD16/CD32 from Biolegend, clone 2.4G2). The Trustain fcX 
block CD16 (low affinity IgG Fc receptor III) and CD32 (Fc receptor II) receptors. The 
antigen-antibody immune complexes bind to Fc receptors and mediate adaptive immune 
responses. These receptors are present on many cells like DCs, mast cells, B cells, NK 
cells, macrophages etc. Using this blocking antibody prevents non-specific binding of the 
cell surface antibodies to the Fc receptors. The samples were incubated for another 15 
minutes with 100ul per well of Fc block in the dark at 4°C. All centrifugation steps were 
done at 400g for 5 minutes at 4°C. The supernatant was decanted, the cells were re-
suspended in 50ul of the staining cocktail which constituted of different cell surface 
antibodies specific for tumor infiltrating lymphocytes. There were 2 staining panels – one 
for staining of the myeloid cell populations (table 8) and the other for NK + T cell 










2.17. Fluorescent antibody panel for myeloid cell analysis 
Cell surface marker Fluorophore Clone  Source  Dilution 
F4/80  Percpcy5.5 BM8 BioLegend 1 to 250 
CD80  Alexa 488 16-10A1 BioLegend 1 to 250 
CD11c  PEcy7 N418 BioLegend 1 to 500 
CD86  PE GL-1 BioLegend 1 to 300 
Ly6G  PE texasRed 1A8 BioLegend 1 to 1000 
CD90.2  Alexa 700 30-H12 BioLegend 1 to 250 
CD19  Alexa 700 6D5 BioLegend 1 to 250 
MHCII  BV421 M5/114.15.2 BioLegend 1 to 500 
CD11b  BV605 M1/70 BioLegend 1 to 2000 
Ly6C  BV711 HK1.4 BioLegend 1 to 1000 
CD45  BUV395 30-F11 BD 1 to 500 
      




2.18. Fluorescent antibody panel for NK and T cell analysis 
cell surface marker Fluorophore Clone Source Dilution 
CD4 PercpCy5.5/PE-cy5 RM4-5 ebioscience 1 to 250 
CD8a PE-Cy7 5.3-6.7 ebioscience 1 to 400 
Foxp3 FITC/Alexa 488 FJK-16s ebioscience 1 to 300 
LIVE DEAD BV510   Biolegend 1 to 1000 
CD45 APC/Cy7 30-F11 ebioscience 1 to 200 
Ki67 PE SolA15 ebioscience 1 to 250 
NK1.1 BV421 PK136 ebioscience 1 to 200 
CD90.2 Alexa 700 30-H12 Biolegend 1 to 250 
CD19 Alexa 700 6D5 Biolegend 1 to 300 
CD27 APC LG.7F9 ebioscience 1 to 250 
CD11b BV605 M1/70 Biolegend 1 to 2000 
FoxP3 TF Staining 




                Table 9: Fluorescent antibody panel for NK and T cell staining 
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The cells were stained with cell surface antibodies for 30 minutes in the dark at 
4°C. After staining, they were washed twice with Facs buffer. The cells were fixed 
overnight in the dark at 4°C in Foxp3 fix-perm buffer, essential for staining intracellular 
antibodies like Foxp3 and CD206, which was done for 30 minutes at 4°C in the dark. 
After fixing the cells, washes were done in 1X perm buffer, in order to keep the cells in a 
permeable state for the intracellular antibodies to enter the cell. For analysis on the flow 
cytometer the cells were re-suspended in 300 to 500 µL FACS buffer and run in HTS 
mode on BD Fortessa. For setting up PMT voltages, compensation controls were 
prepared. Either cells from tumor/lymph nodes or compensation beads were used with 
CD4 or CD19 antibodies for the fluorophores being used. The FACS data was analyzed 
using FlowJo 10.08 software. 
 
2.19. Intratumoral cytokine/chemokine analysis 
Cytokines and chemokine analysis was done using the “MILLIPLEX MAP mouse 
cytokine/chemokine magnetic bead panel – Immunology Multiplex Assay” from 
Millipore. Multiple cytokine and chemokine markers from tumor supernatant were 
analyzed by bead-based Multiplex assay from Luminex Technology. The samples were 
processed as per the manufacturer’s instructions. The assayed beads were then read on a 
Magpix plate reader. 
 
2.20. Statistical analysis 
This was done using GraphPad PRISM. Error bars represent SEM calculated 
using PRISM. For looking into the differences in tumor burden between groups, one way 
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and two-way ANOVA (with Bonferroni posttest) was used. For comparing the 
differences between AHR WT vs AHR KO mice and Vehicle vs CH223191 treated mice 
for different lymphocyte subsets, data analysis was done by the Student’s t test (unpaired) 
using GraphPad PRISM to compare the means of the two study groups. A p value of 
<0.05 was considered as a significant difference. * p < 0.05, ** p <0.005, *** p < 0.0005, 
and ns (not significant) represents p > 0.05 
 




CHAPTER 3: RESULTS 
 
3.1. AHR in MC38 cells drives a modest and short lived cyp1a1 gene expression 
when exposed to TCDD 
 
The aim of this experiment was to elucidate whether MC38, B16F10 and 
Hepa1c1c7 cells expressed AHR and if the receptor was functional, i.e., can drive the 
expression of cyp1a1 and other genes of the AHR gene battery. The nuclear AHR + 
ARNT complex binds to specific promoter regions (DRE-Dioxin response elements) with 
the sequence 5’-T/G/TCGTGA/CG/TA/T-3’ on genomic DNA to enhance the 
transcription of AHR target genes. These are collectively called as the “AHR gene 
battery” – cyp1a1, cyp1b1 (cytochrome P450 I family member a1 and b1), nqo1 (NAD 
(P) H quinone oxidoreductase 1), aldh3a1 (aldehyde dehydrogenase 3 family, member 
a1), ugt1a6 (UDP glucoronosyl transferase 1 family, polypeptide A6) and GST-Ya 
(glutathione S transferase). These genes encode phase I and II metabolizing enzymes that 
are responsible for the detoxification of xenobiotics in the liver. Apart from this, AHR 
plays a role in mediating xenobiotic-independent and physiological functions. To list a 
few, it is involved in reproduction, cell proliferation, apoptosis, tumor suppression or 
progression, and differentiation of immune cells [43]. 
           Cyp1a1 is the quintessential biomarker that is expressed upon exposure to 
halogented hydrocarbons such as TCDD. MC38 (colon carcinoma) and B16F10 
(melanoma) were two transplantable mouse cell lines used for tumor model generation. 
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After treatment with 1nM TCDD in vitro, mRNA levels of ahr and cyp1a1 were 
evaluated in these two cell lines. Hepa1c1c7 (mouse hepatoma) cells which have been 
shown to express ahr and are highly inducible for cyp1a1 expression with TCDD 
treatment, was used for comparison. The mRNA levels of the AHR gene battery were 
measured only in MC38 cells.  
The cyp1a1, cyp1b1 and ahr message levels of Hepa1c1c7 (Fig 3, 4 & 5) in 
comparison to that of MC38 were measured at 6 and 24 hours in the presence or absence 
of 1nM TCDD. The induced expression level of cyp1a1 in Hepa1c1c7 is much higher 
than that of MC38 cells (Fig. 3). There is roughly a two fold increase in the cyp1b1 and 
ahr transcripts in Hepa1c1c7 cells at 24 hours (Fig. 4 and 5). The data was normalized to 















Figure 3: cyp1a1 mRNA levels measured in MC38 and Hepa1c1c7 cell lines, at 6 and 24 
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Figure 4: cyp1b1 mRNA levels measured in MC38 and Hepa1c1c7 cell lines, at 6 and 24 
















Figure 5: ahr mRNA levels measured in MC38 and Hepa1c1c7 cell lines, at 6 and 24 
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To determine the consequences of TCDD incubation of MC38 and to compare to 
B16F10, MC38 and B16F10 cells were exposed to 1nM TCDD. The expression of ahr 
and cyp1a1 were measured at 3, 6, 18 and 24 hours. The message levels of ahr were very 
similar in the two cell lines, but higher in MC38 cells at the 3 hour time point (Fig.6). 
 
 
   









Figure 6: ahr mRNA levels measured in MC38 and B16F10 cell lines, at 3, 6, 18 and 24 




There is little induction of the cyp1a1 message in MC38 cells; it is highest at the 3 
hour period and tapers down thereafter to 24 hours. This suggests that AHR, in the 
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Figure 7: cyp1a1 mRNA levels measured in MC38 cell line, at 3, 6, 18 and 24 hours after 














Figure 8: cyp1a1 mRNA levels measured in B16F10 cell line, at 3, 6, 18 and 24 hours 




By contrast, the cyp1a1 levels of B16F10 were quite steady over the 24 hour 
period and significantly higher than that of MC38 (Fig.8).  
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The message levels of ugt1a, ahrr, cyp1a2, nqo, cyp1b1 were measured in MC38 
cells 24 hours after 1nM TCDD treatment and no detectable expression in the members 
of the AHR gene battery were seen (Fig.9). The mRNA levels at earlier time points were 
not measured. Like cyp1a1 expression in MC38 cells, perhaps the expression for these 
genes occurs for a very short duration (either at 3 hours or within 0 to 24 hour period) and 
if this is the case, the AHR gene battery is active for a very short period and the changes 
might have been missed due to the transient nature of induction. If a sustained AHR 
induction is required, then AHR may not elicit normal functions in MC38 cells and 
perhaps AHR expression in MC38 cells is irrelevant and thus, any effects on tumor 
















Figure 9: AHR gene battery mRNA levels measured in MC38 cell line, at 24 hours after 
1nM TCDD treatment. Data were normalized to the control group, n=3 per experiment. 
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3.2. In vivo TCDD efficacy studies 
According to the stated hypothesis, activation of AHR by its ligands increases 
Treg differentiation; increased Treg differentiation leads to increased immune 
suppression and therefore increased tumor burden. TCDD is a very potent ligand of AHR 
and even small quantities of the toxin can activate AHR, both in vivo and in vitro. TCDD 
is also a potent immune suppressor and is known to increase Treg differentiation in many 
in vivo models [21]. Therefore, TCDD was used as an AHR ligand for in vivo studies. 
The dosage of 1ug/mouse was based on the Quintana et. al paper [21].  
Before administering TCDD in the tumor model, the effects and duration of 
TCDD in vivo were explored. As cyp1a1 is the classic biomarker that is expressed upon 
exposure to TCDD, mice were injected with 1µg/mouse TCDD (administered 
intraperitoneally). Livers were harvested at 72 hours, 7 days and 14 days after TCDD 





                            
















Figure 10: Expression levels of cyp1a1 gene in liver of C57BL/6 mice treated with 
1ug/mouse TCDD, harvested 72 hours, 7 and 14 days. RNA was normalized to the 
control group. 
   
   
 
  The cyp1a1 mRNA levels were measured till day 14 after TCDD treatment from 
livers of treated mice (Fig. 10), demonstrating TCDD activated liver AHR expression 
until at least 14 days. There is more than 2-fold induction on day 14 in comparison to day 
3 (or 72 hours). 
  In two separate experiments the cyp1a1 levels were measured at 48 hours (Fig. 
12) and again on day 24 (Fig. 11) after TCDD administration from MC38 tumor-bearing 
mice. The RT-PCR data from all these experiments demonstrated that TCDD activated 
the receptor as early as 2 days and up to at least 24 days, thus, throughout the duration of 
























   Figure 11: Expression levels of cyp1a1 gene in liver of MC38 tumor bearing C57BL/6 
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Figure 12: Expression levels of cyp1a1 gene in liver of C57BL/6 mice treated with 





3.3. Pharmacologic activation by TCDD (1 dose) does not alter MC38 tumor growth 
The tumor model used to prove the aforementioned hypothesis is the MC38 
syngeneic tumor model. MC38 is a colon adenocarcinoma tumor model on the C57BL/6 
background. This cell line was generated by Corbett et. al in 1975 by chemically inducing 
tumors in C57BL/6 mice. Tumor studies were performed as indicated in the schematic 
below (Fig. 13). TCDD was administered one day prior to MC38 cell implantation so as 
to have AHR activated pre-implantation. The experiment was repeated at least 5 times 
with n = 8 to 12 animals per experiment.  
 
Figure 13: Schematic of MC38 tumor study on C57BL/6 mice; AHR was pharmaco-





Tumors were measured twice weekly using Calipers and the data captured in 
STUDYLOG software. Data from the TCDD treated group was compared to the vehicle 
group, 2% DMSO + corn oil (pharmaceutical grade). The treatment was administered 
once, one day prior to the MC38 implantations. The average tumor burden was the same 
on day 7 for both groups (67mm3). Based on the tumor burden results below there was no 
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Figure 14: MC38 tumor burden in C57BL/6 mice measured on day 7, 10, 14, 17, 21, 24 




3.4. T cell analysis by FACS 
Although there was no change in tumor burden, the T cell compartment in spleen 
and the tumor implant (infiltrating lymphocytes) were characterized on day 14. The T cell 
subsets evaluated were effector CD4+, CD8a and CD4+ Foxp3+Treg populations. The 
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CD8a+ to Foxp3+Treg ratios were also calculated. Analysis of the T cell subsets in 
spleen showed that there was a significant reduction in the effector CD4+ T cells in the 
TCDD treated group in comparison to the vehicle group. The effector CD4+ T cells were 
gated on the total CD45+ lymphocyte population after gating out lymphocytes stained for 
the CD8a+ and CD4+ Foxp3+ Treg lymphocytes. There was a significant increase in the 
splenic Foxp3+ Tregs in the TCDD treated group indicating a peripheral immune 
suppressive phenotype (1.2 fold increase). There was a significant decrease in the CD8a 
to Foxp3+Treg ratio in the TCDD treated spleens suggesting that there was an increased 
number of Foxp3+ Tregs than the CD8a+ cells indicating a peripheral immune 
suppressive phenotype (1.4 fold decrease). There was no change in the percentage of the 
CD8a+ cells in the two groups of mice. 
Analysis of tumor infiltrating lymphocytes revealed that there was no change in 
the effector CD4+ T cells, Foxp3+ Tregs and CD8a to Treg ratio cells in the tumors from 
TCDD and vehicle treated mice. However, there was a significant reduction in the 






   
 
Figure 15: Analysis of T cell subsets in spleen of TCDD and vehicle treated mice with 
MC38 tumor implants. Data are representative of one of the three experiments, with n = 8 











   
Figure 16: Analysis of the tumor infiltrating lymphocytes from MC38 tumors treated with 
TCDD and vehicle treated mice. Data are representative of one of the three experiments, 
with n = 8 animals per group. * p < 0.05, and ns (not significant) represents p > 0.05. 
 
 
The tumor burden and FACS analyses data are consistent with TCDD 
administration causing a peripheral immune suppression in the mouse as indicated by the 
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increase in Foxp3+ Tregs and decrease in the CD8a to Treg ratio, but is neither reflected 
in the T cell subsets of the tumor microenvironment nor the tumor volume. This leads to 
the question if the administration of TCDD – 1ug per mouse given intraperitoneally, was 
sufficient to cause immune suppression. This question was addressed by using the LPS 
mouse model, where humoral responses were measured in response to LPS 
administration in the presence and absence of TCDD. 
 
3.5. Effect of TCDD on LPS elicited humoral challenge 
LPS (Lipopolysaccharide) is a component of the bacterial cell wall and an 
endotoxin which elicits an innate immune response via TLR4 pathway and also a 
humoral immune response mediated by CD4+ T cells. This experiment was based on the 
paper from Kaminski et. al, [44]. The idea behind using this model was to determine if 
the TCDD dosage of 1ug per mouse could suppress activation of humoral responses 
promoted by 25ug of LPS. 
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Figure 17: Schematic of the TCDD-mediated suppression of the humoral response due to 
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Figure 18: Humoral response measured by the frequency of IgM producing plasma cells 
after LPS and TCDD challenge. N = 6 mice / group, *** p < 0.0005 
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Figure 19: Reduced plasma cell numbers in spleen after TCDD and LPS treatment. A. 
FACS plot showing CD19+ CD138+ plasma cells in splenocytes from mice treated with 
TCDD, LPS and controls. B. CD138 + plasma cell numbers after TCDD and LPS 




The experiment was done as described in Fig. 17. Mouse splenocytes were plated 
into a 96 well ELISPOT assay plate and the frequency of the IgM-producing plasma cells 
was measured. There was an increase in the number of IgM-producing plasma cells upon 
LPS challenge. This response was reduced by almost three-fold in mice that were 
exposed to TCDD prior to LPS challenge. In the DMSO + LPS group that received no 
TCDD, the humoral response was similar to the LPS alone group. The untreated group 
did not elicit any humoral response.  
Next, CD138+ plasma cells were enumerated by FACS. Plasma cells are 
terminally differentiated B cells that produce specific antibodies for the antigen they have 







acquire after antigen-driven differentiation. CD19 was also used as a B-lymphocyte 
marker.  
In Fig.19A, LPS challenge in the LPS and DMSO + LPS groups, resulted in 
increased numbers of CD138hi plasma cells. In Fig. 19B, plasma cell populations 
identified as CD19hiCD138hi cells were measured and a 3-fold reduction was observed in 
the TCDD-treated group. Therefore, TCDD at 1ug/mouse suppressed the humoral 
response elicited by LPS challenge as measured by CD19hiCD138hi cells. 
With the FACS analysis of B cells from the LPS challenge and the T cell subsets 
(from spleen and tumor), 1ug/mouse TCDD dose is sufficient to suppress an LPS elicited 
humoral response, the effector CD4+ T cells in the spleen and the CD8+ T cells in the 
tumor. However this dosage has no effect on tumor volume. Therefore, it was decided to 
increase the TCDD dosing frequency, but below the lethal dose of TCDD (LD50), namely 
160ug/kg for C57BL/6 [29]. 
 
3.6. Pharmacologic activation by TCDD (administered 3 times) suppresses MC38 
tumor growth 
The tumor model was generated in a similar fashion to the schema described in 
Fig. 13, except for the TCDD dosing regimen. TCDD was administered on days 7, 10 and 
15 at 1ug/mouse. The body weights of these mice were measured along with the tumors 
twice weekly; there were no gross changes in body weight or the apparent health of the 
mice. The tumor burden in the group that received TCDD started to show reduced  
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Figure 20: MC38 tumor burden with TCDD dosed on days 7, 10 and 15. This experiment 
was done twice with n= 16 mice per group. *** p < 0.0005, * p < 0.05 
 
 
            
Figure 21: MC38 tumor burden comparing mice dosed with TCDD days 7, 10 and 15 






tumor growth starting day 17 and there was a significant reduction in tumor burden in 
comparison to the vehicle group starting day 21.  
The body weights of mice were measured each time the tumor was measured. 
This was done to ensure that the TCDD administration and tumor implantation did not 
affect the health of the mouse. The graph below is one representative of multiple studies. 
In Fig. 22, all mice seemed to be healthy except for one mouse (received 3 doses of 
TCDD) that was sacrificed on day 14 for exhibiting moribund symptoms and 2 mice that 
were sacrificed around day 20 due to losing more than 20% of the body weight; one 
mouse received 1 dose of TCDD and reached a tumor endpoint (2084mm3 volume) and 




Figure 22: Body weight (in grams) of all the mice on study were measured using a 








































The tumor infiltrating lymphocytes on day 14, i.e, 7 days after the first TCDD 
treatment were evaluated. Among the T cell subsets analyzed, there was a change only in 
CD8a+ lymphocytes (Fig. 24) - there was a reduction in CD8a+ T lymphocytes in the 
groups of mice that received two doses (where a significant reduction in tumor burden 
was seen) and one dose of TCDD (where no change in tumor burden was seen) in 
comparison to the vehicle group. Therefore, there is no correlation between the reduced 
tumor infiltrating CD8 + T cells to changes in tumor burden. The CD8+ T cells are very 
sensitive to TCDD and these reductions could be a direct result of TCDD-mediated 
immune suppression [45]. 
 
  
                        
Figure 23: Graph compiling all the tumor infiltrating T cell subsets analyzed on day14 (or 
7 days after TCDD treatment) in mice that received 2 doses of TCDD, 1 dose of TCDD 





                       
Figure 24: Graph compiling the tumor infiltrating CD8a + T cells analyzed on day14 (or 
7 days after TCDD treatment) in mice that received 2 doses of TCDD, 1 dose of TCDD 




3.7. MC38 tumor burden experiments with different vehicles 
Differences in MC38 tumor burdens in AHR WT mice between TCDD and 
different vehicles were evaluated to rule out any effects caused by DMSO and corn oil on 
tumor burden. This experiment was done once with an n = 12 animals per group. The 
TCDD and the vehicles were administered intraperitoneally on day 7 after the mice were 
randomized by tumor volume and divided into 4 groups with the same average tumor 
burden per group. There were no statistically significant differences between any of the 
groups and thus no consequence of the vehicle to tumor growth. Notably, the 1X PBS 






Figure 25: MC38 tumor burden experiment done with TCDD and different vehicles to 
rule out any vehicle mediated effect on the tumor growth. No statistically significant 




3.8. AHR absence either genetically or by pharmacologic blockade showed enhanced 
MC38 tumor growth 
Experiments with the AHR agonist TCDD have shown that increasing the dosing 
frequency reduces the MC38 tumor burden. This prompted experiments to determine the 
consequence to MC38 tumor burden in 1) the context of pharmacological blockade of the 
receptor using an antagonist and 2) in the absence of the receptor, by using AHR KO 







3.9. CH223191 blocks TCDD mediated cyp1a1 induction in liver 
Before the AHR antagonist molecule CH223191 was used, preliminary studies 
were undertaken to define the dosing regimen and route of administration. CH223191 at 
10mg/kg body weight was administered 48 hours prior to TCDD administration (which 
amounts to 0.5µg of CH223191 per mouse). Three mice per group were used. Livers 
from mice were harvested 3 and 6 hours post TCDD administration.  
 
 
                     cyp1a1 expression                                                        ahr expression
 
Figure 26: Message levels in liver of mice treated with CH223191 and TCDD. A) cyp1a1 




Total RNA was extracted and RT-PCR performed to quantitate cyp1a1 and ahr message 
levels. CH223191 blocked TCDD mediated cyp1a1 induction as early as 3 hours post-
administration but reached significance only at 6 hours.  
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As such, CH223191 was used at 10mg/kg body weight for all the subsequent tumor 
experiments. In the tumor studies, because no TCDD was administered, CH223191 is 
blocking endogenous AHR ligands. 
 
                   
Figure 27: Structure of AHR antagonist – CH223191 (- 2-Methyl-2H-pyrazole -3-  




Below is the schematic of the MC38 tumor burden study used for antagonizing AHR. 
 
3.10. MC38 tumor burden studies by antagonizing the receptor 
             
  
Figure 28: Schematic of tumor study. Note the daily administration of CH223191, 






CH223191 was orally administered daily using feeding needles, starting from day 
7 until the end of study. CH223191 was dissolved in 2% DMSO + corn oil which was also 
the vehicle control. CH223191 was kept at 4°C as a 25 mg/mL stock and a fresh solution 
was prepared for every administration. These tumor burden studies were repeated at least 
three times with an n = 8 to 12 mice per group. 2 X 106 MC38 cells were implanted on the 
right flank of the mice and tumors and body weights measured twice weekly.  
The mice on the study were in good health and the administration of the 
compound did not cause any adverse effects in mice. The mice that exhibited ulcerated 
tumors were removed from the study and were excluded from the tumor volume 
measurements. In the tumor burden data represented in Fig. 26, tumors on 3 mice (out of 
10) were found ulcerated on day 17 and were removed from the experiment.  We started 
seeing significant changes in the tumor burden starting on day 17. The study was 
terminated around day 21 as most of the mice in the study had reached the maximum 
tumor volume of 2000mm3 or exhibited tumor ulcerations. Therefore, antagonizing the 





                  
 Figure 29: Pharmacologic blocking of AHR by CH223191 increased MC38 
tumor burden in C57BL/6 mice. N = 10 mice per group on day 0.  
 
 
3.11. MC38 tumor burden experiments with AHR deficient mice 
The tumor burden experiments using AHR KO and WT mice were done as 







   Figure 30: Schematic of tumor study for AHR WT and AHR KO mice 
 
 
The mice used for the study were bred at BMS animal facility and were originally 
created in Chris Bradfield’s lab [46]. On day 7, the first day of the measurement, mice 
were not randomized but the average tumor burdens between the WT and the KO mice 
were similar after excluding low and high tumor burden outliers, which resulted in 8 to 
10 mice per group. Differences in tumor burden were observed on day 17 and were 
significant on day 21. Indeed, the tumor burden in the AHR KO mice was almost twice 
the volume as compared to their WT counterparts. The experiment was repeated at least 





Figure 31: MC38 tumor burden is increased in AHR deficient mice in comparison to 
AHR proficient mice. 2 X 106 MC38 cells were implanted on day 0. Tumor volumes were 




3.12. B16F10 tumor model 
To confirm and extend to a different tumor model, studies were performed using 
the B16F10 tumor model in both AHR antagonist treated and AHR deficient (AHR KO) 
mice. B16F10 is an aggressive C57BL/6 melanoma cell line that is considered poorly 
immunogenic in vivo. A pilot study was conducted to determine what cell number would 
be sufficient, so as to have palpable tumors by day 6 or 7. It was emperically determined 
that one million cells would result in palpable tumors by day 6. The experiment was done 
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once each with the antagonist and once in AHR deficient mice. A starting number of 12 
mice per group were used in each experiment. 
 
3.13. B16F10 tumor-bearing mice treated with AHR pharmacologic blockade did 
not exhibit any significant differences in the tumor burden 
 
 
Figure 32: B16F10 tumor burden in C57BL/6 mice in the presence of AHR antagonist 




The study shown in figure 31 was done using one million cells for implantation. 
On day 7, tumors were measured, mice were randomized based on tumor burden, then 
divided into the treatment and control groups. The antagonist (CH223191) or vehicle was 
administered every day orally starting from day 7 and continued until the end of the 
study. There were no significant changes in the tumor burden until day 16 post-
implantation. The study had to be prematurely terminated because many mice developed 
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ulcerated tumors and their health status began to decline. The latter was monitored by the 
animal weight and general health (lethargy, moribund, failure to thrive, posture, tented 
skin and/ or weight loss were monitored). 
 
3.14. B16F10 tumor burden using AHR deficient mice 
One million B16F10 cells were implanted in AHR WT and AHR KO (AHR-/-) 
mice bred at the Bristol-Myers Squibb Company animal facility. Genotypes of the mice 
used in the study were confirmed by PCR using DNA extracted from tails and specific 
primers. The tumor measurements started on day 7 and the co-housed mice did not 
receive any treatments. The study was done once with 10 to 11 mice per group. 
 
                  
Figure 33: B16F10 tumor burden in AHR deficient mice resulted in significant increase 




There were significant changes in the tumor burden on day 16 after the subcutaneous 
implants (P = 0.002). The tumors grew faster in the absence of AHR in comparison to 
their WT counterparts. The study had to be terminated by day 16, because many mice 
developed ulcerated tumors and their health status began to decline. The latter was 
monitored by the animal weight and general health (exhibited signs of lethargy, 
moribund, failure to thrive, posture, tented skin and or weight loss). 
 
3.15. Immune profiling of the MC38 tumor microenvironment 
 
Based on the tumor burden data obtained from the agonist, antagonist and the KO 
studies, the data suggest that absence of AHR signaling increases the MC38 tumor 
burden. The tumor environment was analyzed to determine if the increased tumor burden 
could be attributed to the changes in the infiltrating lymphocytes and cytokines in the 
tumor milieu. 
Immune phenotyping of the T, NK and myeloid populations were done. Immune 
cells are distinguished based on a signature through the expression of specific surface 
proteins. Immune phenotyping is a technique of identifying cells by their cell surface and 
cytoplasmic protein expression using a specific antibody tagged to a fluorescent moiety. 
The stained samples are then run through a flow cytometer, a laser based instrument that 
counts cells based on the gate set for the fluorescent tagged antibodies. The samples were 




As stated earlier, differences in MC38 tumor burden in the studies with AHR KO 
mice and the antagonist CH223191 became noticeable starting day 17. The tumors and 
draining lymph nodes were harvested on day 17. Two FACS antibody staining panels – 
one for the myeloid cells/dendritic cells and the other for T/NK cells – were used. Tissues 
were harvested in RPMI + 10% FBS and homogenized using the gentleMACSTM tissue 
grinder (Miltenyi Biotech). The disrupted tissues were then digested with a mixture of 
collagenase IV and DNase I enzymes, to release myeloid cell populations embedded in 
the tissue. The samples used for T/NK cells were also treated similarly and notably the 
enzyme digest did not adversely affect the detection of cell surface staining markers.  
 
3.16. Myeloid population gating strategy 
In the myeloid population, cells were first gated on singlets (doublets were 
excluded from the analysis), then the live population followed by CD45 staining 
lymphocytes. T and B cells were excluded using the dump channel for CD90.2 and CD19 
antibodies, respectively. From the T and B cell excluded population denoted as ‘minus T 
cells’, neutrophil and monocytes (Ly6C positive) were identified. From the remainder of 
the cells, MHC II positive cells were gated. Thereafter, F4/80 positive tumor-associated 
macrophages (TAMs) and CD206 positive M2 macrophages were gated. Dendritic cells, 
identified by the markers CD11b, CD24 and CD103 were also enumerated in addition of 
the evaluation of dendritic cell activation markers CD80 and CD86. The myeloid cell 
gating strategy is shown below (Fig. 34) using a single cell suspension of tumor cells 





















3.17. T cell gating strategy 
 
 
Figure 35: T cell gating strategy for AHR WT, AHR KO and WT +/- CH223191 treated 
mice 
 
From the tumor single cell suspension, cells were first gated on singlets (doublets 
were excluded from the analysis), then the live population and then CD45 positive 
lymphocytes. CD4 positive and CD8a positive T cells were gated from the CD45 positive 
lymphocyte population. The Foxp3 positive T regulatory cells were gated from the CD4+ 
T cell population. To identify proliferating Foxp3+ T regulatory and CD8a + cells, the 
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cell surface marker Ki67 was used. The proliferating Foxp3hi T regs were noted to be 
Ki67hi. The proliferating CD8ahi cells were also Ki67hi.  
 
 
3.18. NK (Natural killer) cell gating strategy 
 
 





From the singlet cell gate (doublets were excluded from the analysis), live cells 
and then lymphocytes were gated. From the lymphocyte population the T and B cells and 
NK1.1+ cells were gated. The T and B cells were excluded using the dump channel for 
CD90.2 and CD19 antibodies, respectively. The NK1.1+ population were further gated 






3.19. Immune phenotyping results in AHR WT and AHR KO mice 
FACS analysis of tumor implants and draining lymph nodes (dLNs) harvested on 
day 17 from AHR WT and KO mice revealed increased MC38 tumor burdens resulted in 













      
Figure 37: A) Increase in MC38 tumor burden in AHR KO did not result significantly 
increased Foxp3+ Tregs. B) Number of Foxp3+ Tregs in AHR WT and AHR KO mice in 
draining lymph nodes (dLNs). C) Increased MC38 tumor burden in AHR KO mice 
resulted in a reduction of CD8a + T cell infiltration. D) Number of Foxp3+ Tregs in AHR 
WT and AHR KO mice in dLNs. E) CD8a to Foxp3+ Treg ratio significantly reduced 
with increase in tumor burden. These data are a representative of 2 experiments. * p < 
0.05, **** p < 0.0001, and ns (not significant) represents p>0.05 
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In tumors there was a significant decrease in CD8a+ T cells and the CD8a to 
Foxp3+ Treg ratio associated with increased tumor burden. By contrast a significant 
increase in the CD8a + T cells was detected in the dLNs of AHR KO mice. The 
proliferating marker Ki67 was used to stain Foxp3+ Tregs and CD8a+ T cells and there 
were no differences in its expression in the tumors from AHR WT versus KO mice. This 
suggests that there is no increased proliferation of these two cell populations but the 
increased numbers seen in the tumor may have resulted from increased infiltration.  
Analysis of NK cells using the cell surface markers – NK1.1 and CD27 revealed 
reduced numbers with increased tumor burden in the AHR KO mice. 
Figure 38: A) NK1.1 cells reduce in numbers with increase in tumor burden. B) Reduced 
CD27+ NK1.1 cells in AHR KO mice with increase in MC38 tumor burden. These data 




Next, the myeloid populations in the MC38 tumor microenvironment were 
characterized. There was no change in the infiltrating monocytes (Ly6C positive) or 
neutrophils. The dendritic cell subsets represented by the cell surface markers CD103, 
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CD11b, CD80 and CD86 were evaluated and there were no changes in the two groups of 
mice. However, there was a significant increase in the F4/80 positive TAMs and the 
CD206 positive M2 macrophages, although there was also no change in their MHCII. 
The tumor burden experiments involving the AHR WT and KO mice were repeated twice 





     
 
Figure 39: A, B, C, D) No change in monocyte, neutrophil, CD11b DCs and CD103 DCs 
with increased MC38 tumor burden in AHR KO mice. E) F4/80+ TAMs increased with 
increased tumor burden. F) CD206 macrophages increased with increased MC38 tumor 
burden. These data are a representative of 2 experiments. *** p < 0.0005, and ns (not 





3.20. Immune phenotyping results in AHR WT mice treated in the presence and 
absence of the antagonist CH223191 
 
 
Figure 40: A) Increased MC38 tumor burden in CH223191 treated mice did not result in 
increased Foxp3+ Tregs. B) Number of Foxp3+ Tregs in the dLNs of c57BL/6 mice +/- 
CH223191. C) Increased MC38 tumor burden in CH223191 treated mice associated with 
a reduction in CD8a + T cell infiltration. D) Number of CD8a+ cells in the dLNs in the 
two treatment groups E) CD8a to Foxp3+ Treg ratio significantly reduced with increased 
tumor burden. These data are a representative of 5 experiments, each starting n=10 per 
group per experiment. * p < 0.05, and ns (not significant) represents p > 0.05 
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FACS analysis of tumors and dLNs on day 17 after tumor implants in MC38 
tumor-bearing mice treated with CH223191 and vehicle, revealed that increased tumor 
burden was associated with a very modest, but insignificant increase in Foxp3+ Tregs in 
the tumors, although there was a significant decrease in the CD8a+ T cells with increased 
tumor burden in the antagonist treated mice. However there were no changes in the CD8a 
+ population in the dLNs. There was a significant decrease in the CD8a to Foxp3+ Treg 
ratio with increased tumor burden. There was no change in Ki67 staining in Foxp3+ 
Tregs and CD8a+ T cells from mice treated with the antagonist and the vehicle. This 
suggests that again, there is no increased proliferation of these two cell populations. The 
increased numbers seen in the tumor may have resulted from increased infiltration.  
Reduced NK cell numbers were seen with increased tumor burden in the 


























Figure 41: A) NK1.1 cells reduce in numbers with increase in tumor burden. These data 






































Figure 42: A, B, C, D) No change in monocyte, neutrophil, CD11b DCs and CD103 DCs 
with increase in MC38 tumor burden in CH223191 treated mice. E) F4/80+ TAMs 
increase with increase in tumor burden. F) CD206 macrophages increase with increase in 
MC38 tumor burden. These data are a representative of 5 experiments with a starting n = 






Figure 43: Surface expression of activated DC markers CD80 and CD86 showing no 
changes in the CH223191 treated group with increased MC38 tumor burden 
 
The myeloid populations in the MC38 tumors from mice treated with either 
CH223191 or vehicle were similar to that of AHR WT and KO mice: there were no 
changes in infiltrating Ly6C positive monocytes and DC subsets, -represented by the cell 
surface markers CD103, CD11b, CD80 and CD86 (gated from MHC II high population) 
in the two groups of mice. However, there was a significant increase in the F4/80 positive 
tumor associated macrophages and the CD206 positive M2 macrophages. The tumor 
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burden experiment involving mice treated with either CH223191 or vehicle was repeated 
5 times with a starting n = 10 animals per group in each experiment. 
 
3.21. Intratumoral cytokine and chemokine analysis 
The tumors from AHR WT, AHRKO, vehicle and CH223191 treated mice were 
harvested in RPMI-1640 medium using the gentleMACSTM tissue grinder. The samples 
were then centrifuged, and supernatants flash frozen on dry ice and stored at - 80°C 
freezer for cytokine/chemokine analysis. These analyses was done on thawed samples 
using Millipore’s bead based Luminex assays and run on Magpix. Cytokines secreted by 
Th17 cells, namely IL17A, IL 17F, IL21 and IL22, were analyzed but due to low 
concentrations could not be plotted. Among other measurable cytokines, the levels of 
eotaxin a chemokine secreted by T cell types in response to IL-4 and IL-13 (secreted by 









                  
Figure 44: Amount of intratumoral cytokines/chemokines compared between AHR WT 
vs AHR KO mice and Vehicle vs CH223191 treated mice. A) CD40L. B) Eotaxin, C) 
IFN-γ and D) RANTES (CCL5). Statistical analysis was done using unpaired student’s t 













In the data shown in Fig.43, the levels of eotaxin were significantly lower for the 
AHR KO mice than the WT mice, although there were no difference in tumors from mice 
treated with vehicle and antagonist. The levels of IFN-γ and RANTES (CCL5) were 






Figure 45: Amount of intratumoral cytokines/chemokines compared between AHR WT 
vs AHR KO mice and Vehicle vs CH223191 treated mice. A) IL-1α. B) IL-1β. C) IL-6. 
D) IL-10. Statistical analysis was done using the unpaired student’s t test. * p < 0.05, ** p 





Figure 46: Amount of intratumoral cytokines/chemokines compared between AHR WT 
vs AHR KO mice and Vehicle vs CH223191 treated mice. A) IL-12p70. B) IL-13. C) IP-







Table 10: The amount of cytokines/chemokines (in pg/ml) in AHRWT vsAHRKO mice 
and vehicle (Veh) vs CH223191 (CH) treated mice. Statistical analysis was done using 
the unpaired student’s t test. * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001, 
and ns (not significant) represents p > 0.05 
 
 
Based on the graphs in figures 43, 44 and 45 and table 10, there were no changes 
in the levels of IL-1α, IL-2, IL-13, IL-10, MIG (CXCL9) and VEGF. There was a 
significant increase in the pro-inflammatory cytokine IL-6; a reduction in IL-1β and 
TNF-α in the AHR KO and antagonist-treated mice as tumor burden increased. 
Conversely, there was a reduction in the amount of IL-10, an anti-inflammatory cytokine, 
in the AHR KO and antagonist-treated mice as tumor burden increased. IL-12 is a 
cytokine involved in the differentiation of Th1 cells, mainly secreted by the DCs, that 
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helps activate effector T cells and NK cells, is involved in the IFN-γ production and 
activation of anti-tumor immunity. The amount of IL-12p40 subunit cytokine was 
reduced in both groups with increased tumor burden but it was significantly reduced in 
the antagonist-treated group. The IL-12p70 subunit reduced in both treatment groups with 
increased tumor burden. RANTES/CCL5 is a chemoattractant for T cells, basophils and 
other leucocytes. CCL5 expression is known to increase in tumors, causes inflammation 





























CHAPTER 4: DISCUSSION 
 
AHR is known to play a dual role in cancer progression and the tumor progression 
or suppression is related to the target cell phenotype. There are not many in vivo tumor 
studies analyzing the role of AHR in colon carcinogenesis. Although AHR (-/-) mice 
have an increased incidence of intestinal inflammation and colo-rectal tumors, this 
pathology could be reversed with treatment by AHR-agonists [38]. To elucidate the role 
of AHR in cancer, a mouse colon carcinoma syngeneic model was used. The following 
hypotheses were proposed based on AHR-research findings that, AHR activation by 
TCDD, results in increased Tregs and decreased T effectors such as CD8+ T, cells 
leading to tumor progression. 
Hypothesis 1 
T regulatory cells suppress anti-tumor immunity by inhibiting cytotoxic T 
lymphocytes (CD8 + T cells). Activation of AHR by agonists increased the differentiation 
of naïve T cells into T regulatory cells. Therefore activation of the AHR with an exogenous 
agonist in tumor-bearing mice should increase the tumor burden. 
Hypothesis 2 
If endogenous ligands help to maintain tumor surveillance to suppress tumor 






Testing the hypothesis 
MC38 and B16F10 syngeneic models were employed to explore the relevance of 
AHR in MC38 and B16F10 tumor progression. AHR activity in MC38 and B16F10 cells 
was assessed by measuring the expression of two AHR-responsive genes, cyp1a1 and 
cyp1b1. Cyp1a1 is the classic marker of this receptor that is expressed upon exposure to 
TCDD, a potent AHR agonist. In vitro tumor cells were exposed to 1nM TCDD and cyp1a1 
expression was determined at 0, 3, 6, 18 and 24 hour post treatment. In MC38 cells,  cyp1a1 
expression was highest at the 3 hour time point and tapered down over 24 hours. Contrary 
to this, the expression in B16F10 cells was quite steady over 24 hours. The cyp1a1 
expression in MC38 cells is short lived and lower in comparison to that of B16F10.  
After nuclear localization of ligand-bound AHR, a set of genes is induced, termed 
as the AHR gene battery. These genes co-induced as a result of AHR activation vary 
depending on the cell type and species [47]. TCDD activation of AHR led to altered 
expression of 379 genes in kidney and 471 in liver [48]. The expression of the following 
AHR battery genes, - cyp1a1, 1a2, 1b1, nqo, ahrr and ugt1a6 were measured in MC38 
cells after exposure to 1nM TCDD for 24 hours and their expression was not detectable. 
Perhaps their expression  like cyp1a1 is for a shorter duration, within the 0 to 24 hour 
period. If so, then AHR gene battery is active for a very short period and AHR may not 
elicit normal functions in MC38 cells. Therefore, any changes in the tumor burden will 
likely be mediated by AHR from stromal cells and tumor infiltrating lymphocytes without 
contribution from MC38 cells. 
 It has been reported that AHR (-/-) mice are refractory to TCDD exposure and do 
not activate the AHR target genes [49].   
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  TCDD, which is a high affinity AHR ligand, was employed in the MC38 tumor 
burden studies to activate the AHR pathway. TCDD was administered intraperitoneally at 
1ug per mouse, one day prior to the MC38 implants. Because TCDD is a hydrophobic 
compound, it was dissolved in DMSO and administered with corn oil as the vehicle. The 
control group was DMSO in corn oil. No modulation in tumor burden was observed 
between the tumor bearing treatment and control groups of mice. T cell analysis by flow 
cytometry from spleens and tumors were done on day 14 after tumor implants. These 
revealed increased Foxp3+ Tregs, decreased CD8a: Treg ratio and CD4 effectors in spleen, 
and a decrease in CD8+ T cells in the tumors of dioxin-treated mice. Tregs are important 
mediators of immune suppression and peripheral tolerance, helping maintain homeostasis 
in the immune system which is essential to prevent auto-immunity and alleviate 
inflammation after infection or injury. Increased Tregs have been seen in tumors and 
immune suppression, tumor progression and poor prognoses of tumors have been attributed 
to increased Tregs [52]. Based on the increased Treg numbers by FACS, in spleen and not 
tumors is an indication that there is immune suppression in the mouse but not in the MC38 
tumor environment.  
This led to the question whether TCDD dose of 1ug/mouse was sufficient enough 
to cause immune-suppression in the mouse. The lipopolysaccharide (LPS) model was used 
to address this question [44]. Here, humoral responses are elicited by IgM- producing 
plasma cells in response to LPS (25ug per mouse, i.p. administration). LPS is a bacterial 
endotoxin, a component of the cell wall of gram negative bacteria, and is highly 
immunogenic. It activates innate immunity via the TLR4 pathway leading to increased 
activation of the transcription factors – NF-kB/AP-1. This leads to activation of humoral 
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immunity by increased antigen presentation through APCs. There was a 3-fold reduction 
in IgM producing plasma cells in the TCDD treated mice in comparison to the LPS alone 
and DMSO + LPS groups (Fig. 17). This was accompanied by a roughly 3-fold reduction 
in the CD19hi CD138hi cells in the TCDD-treated mice (Fig 18). The 1ug/mouse TCDD 
dose and IP route of administration causes immune suppression and this same dose did not 
modulate tumor burden.  
Perhaps TCDD is not reaching the MC38 tumor and therefore increasing the TCDD 
dosing frequency was evaluated. One microgram of TCDD was administered IP on three 
days-7, 10 and 14 after MC38 implantations. Dosing mice three times resulted in a 
significant decrease in tumor volume by day 21 in the dioxin-treated group. It is assumed 
that the decreased tumor volume resulted from receptor agonism as this was not formally 
demonstrated herein.  
As MC38 tumor volumes decreased with increased AHR agonism, tumor burden 
studies were done to further explore this observation. Tumor burden studies in AHR-
deficient mice (AHR KO) and by pharmacologic blockade of the receptor were evaluated. 
AHR WT and AHR KO mice in the tumor study did not receive any therapeutic treatments. 
There was a nearly three-fold increase in the tumor burden in the AHR KO mice as 
compared to the AHR WT mice. To pharmacologically block the receptor, the MC38 tumor 
bearing mice were treated with 10 mg/kg of the CH223191 antagonist, administered orally 
daily, starting from day 7 until the end of the study. CH223191 is a small molecule 
antagonist of AHR, discovered from a random library screening campaign [15]. It is a pure 
antagonist in that concentrations up to 100 µM did not exhibit agonist-like activity or bind 
to other nuclear receptors such as the estrogen receptor. It brings about its antagonistic 
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function by blocking the binding of TCDD to AHR thereby preventing the TCDD-
mediated nuclear translocation [15]. There was a significant increase in the tumor burden 
on day 17 (one-fold) and day 21 (1.5-fold) in mice that received CH223191 treatment. The 
data presented herein show the tumor burden increases in AHR-deficient mice and also 
when the receptor is pharmacologically blocked, suggesting a role for AHR in modulating 
MC38 tumor growth. Increased tumor growth with AHR antagonist is consistent with a 
role for endogenous ligands to maintain tumor burden under some level of control. Lack 
thereof allows tumors to grow faster. Increased tumor burden resulting from AHR blockade 
with CH223191 suggests the presence of endogenous AHR ligands that inhibits tumor 
growth. These endogenous ligands could be derived from a dietary source or produced by 
the animal.  
Tumor studies were also performed on B16F10, a melanoma model to confirm the 
results seen in MC38 studies. There was a significant increase in the B16F10 tumor burden 
in AHR KO mice on day 16 after the implant. This is similar to that seen in MC38 tumors, 
where tumors grew faster in the absence of the receptor in AHR KO mice in comparison 
to WT mice. Increased B16F10 tumor growth in AHR KO mice was also reported by 
Sunwoo and colleagues [25]. The antagonist was administered daily at 10 mg/kg body 
weight, starting day 7 until the end of the study. No changes in tumor burden were seen in 
B16F10 model when the receptor was pharmacologically blocked by CH223191. This 
could be because the B16F10 tumors are resistant to treatment [53] and perhaps the 
antagonist dose was not sufficient to reduce tumor burden.  
 A comprehensive panel of TILs comprising of NK cells, T cell subsets and myeloid 
cell populations from AHR-deficient and AHR antagonist-treated mice along with their 
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wild type counterparts were analyzed by flow. The T cell, myeloid and NK cell gating 
strategy is shown in figures 33, 34 and 35. There was a reduction in total NK cell numbers 
and CD27+ activated NK cells (CD27 data with CH223191 treatment has not been shown 
here) with increased tumor burden. The data agree with those shown by Sunwoo et.al, [25] 
in that AHR was shown to be essential for the cytolytic activity of NK cells. This was 
manifested by an increased tumor burden in RMA-S mouse tumor model in AHR -/- mice.   
Analysis of the myeloid populations demonstrated that there were no changes in the 
infiltrating Ly6C + monocytes or neutrophils. Dendritic cells are the primary antigen 
presenting cells and there was also no change in the infiltrating DCs, the classical DCs 
(CD11b+), cross presenting DCs (CD103) and activated DCs (CD80+ and CD86+) with 
increased tumor burden. However, a significant increase in F4/80 positive tumor-
associated macrophages (TAMs) and CD206 positive macrophages was seen. TAMs are 
most frequently found in the TME and express CD206, CD163 and CD68 as cell surface 
markers. These are differentiated myeloid populations with immune suppressive 
properties; they secrete anti-inflammatory cytokines like interleukin-10 (IL-10) and tumor 
growth factor-β (TGF-β). Macrophages can be re-programed; for example, treatment of 
macrophages in 4T1 and B16 tumor-bearing mice with antibodies to MARCO receptor, 
suppressed tumor growth [33]. The CD206 positive macrophages or M2 macrophages are 
thought to be anti-inflammatory, immune suppressive and promote angiogenesis and tumor 
growth [54]. Goudot et. al, have shown in in-vivo and in-vitro that AHR regulates 
monocytes to differentiate into monocyte-derived dendritic cells as opposed to monocyte 
macrophages via MAF B and IRF 4 [55]. In the data shown herein, increased tumor burden 
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in AHR KO and AHR WT-CH223191 mice led to increased F4/80 + TAMs and increased 
M2 macrophages.   
In-vitro, monocytes can be differentiated into macrophages by stimulating them 
with M-CSF (macrophage-colony stimulating factor) and then polarizing them to either 
M1 or M2 macrophages. Use of IFN-γ leads them to differentiate into the M1 phenotype 
and IL-4 / IL-10 leads them to the M2 phenotype [54]. 
T cell analysis in tumors revealed a significant decrease in cytotoxic T lymphocytes 
(CD8a positive) and the CD8/Treg ratio with increase in tumor burden. There was a modest 
increase in the number of Treg with increase in tumor burden however this was not 
significant. One of the reasons for reduced Foxp3+ Tregs could be due to reduced 
kynurenine levels in the MC38 tumor microenvironment (TME). The kynurenine levels in 
the tumors were not measured but notably MC38 cells do not express IDO, the enzyme 
involved in the metabolism of tryptophan. Kynurenine is an endogenous AHR ligand 
produced by tryptophan metabolism and is known to mediate the differentiation of Treg 
cells [56]. The lack of difference in the Foxp3+ Treg numbers between the different 
treatment groups could also be due to their reduced infiltration into tumors. The 
proliferation of Foxp3 + Tregs and CD8a+ T cells was assessed using Ki67 (data not 
shown) proliferating marker.  Ki67 is a cellular marker for proliferation, present in the G 
(1), S, G (2) and mitosis, active phases of the cell cycle, but absent in G (0). Therefore, 
only proliferating cells will express this marker. There was no change in the expression of 
Foxp3hi Ki67hi and CD8ahi Ki67hi in AHR WT versus KO and in AHRWT+/- CH223191 
mice. This suggests that the reduced cytotoxic lymphocytes is due to reduced infiltration 
of these cells into the tumor environment and not due to reduced proliferation. The role 
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AHR plays in CD8 positive cytotoxic lymphocytes is not very well understood. 
Traditionally CD8+ TILs recognize the tumor antigens and mediate the killing of tumor 
cells through the catalytic action of secreted cytotoxins, such as perforin, granzyme B and 
granulysin. But, this has proved to be controversial as they are known to switch roles and 
become either tumor promoters or suppressors [34]. These molecules were not evaluated 
in the studies described herein. From human tumors, CD8 + TILs have been found to be 
functionally inactive by virtue of reduced proliferation and secretion of less IFN-γ [57]. 
CD8+ populations in tumors are known to exhibit exhaustion, anergy and senescence 
phenotypes [58], rendering them incapable of immune surveillance. The CD8+ TILs from 
AHR KO and AHR WT-CH223191 treated MC38 tumor bearing mice need to be further 
characterized to better understand their phenotype. 
Intratumoral cytokine analysis of the MC38 tumor microenvironment from AHR 
KO and CH223191 treated wild-type mice, revealed an increase in pro-inflammatory 
cytokine interleukin -6 (IL-6) and a reduction of tumor necrosis factor – α (TNF-α) and 
interleukin-1β (IL-1β) with increased tumor burden. There was a reduction in the amount 
of interleukin-10 (IL-10), an anti-inflammatory cytokine, in the AHR KO and antagonist 
treated mice as tumor burden increased. The levels of interleukin-10 are usually increased 
in the TME with increase in tumor burden [33]. But reduced IFN-γ and IL-10 levels have 
been seen in CH223191 antagonist treated lymphokine activated killer cells or NK cells. 
Also, NK cells from AHR(-/-) mice exhibited a defect in IL-10 expression with T.gondii 
infection [59]. Therefore, reduced IL-10 and IFN-γ levels could be a result of reduction or 
lack of AHR activity. The reduced IFN-γ levels in the absence of AHR agrees with that 
reported by Sunwoo et al, [25], as well as increased tumor burden with reduced AHR 
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mediated NK cell activity. IL-12 is a cytokine that is involved in the differentiation of Th1 
cells, mainly secreted by the DCs, which helps activate effector T cells and NK cells, and 
is involved in the IFN-γ production and activation of anti-tumor immunity. The amount of 
IL-12p40 subunit cytokine does not change in the AHR WT vs AHR KO mice, however 
the levels are significantly lower in the CH223191 treated group with increased tumor 
burden. IL-12p70 subunit was reduced in both treatment groups with increased tumor 
burden. The role AHR plays in IL-12 secretion is not well understood, although high levels 
of IL-12 have been reported in AHR null mice when splenocytes were stimulated with ova 
peptide [60].   RANTES/CCL5 is a chemoattractant for T cells, basophils and other 
leucocytes. CCL5 expression is known to increase in tumors, causes inflammation and 
apoptotic killing of CD8 + T cells [61]. Reduced CCL5 levels with increased AHR-
mediated MC38 tumor burden were observed. The role of AHR in mediating CCL5 
expression in the context of the tumor environment is not well understood, although AHR 
ligands (FICZ and BaP) reduced CCL5 mRNA and protein levels in the HaCaT (human 
keratinocyte) cell line [62]. Cytokines secreted by Th17 cells, namely IL17A, IL 17F, IL21 
and IL22 were also evaluated but were out of range of the standard curve and could not be 
plotted. Levels of Eotaxin or CCL11 were found to be significantly reduced in the AHR 
KO mice. There were no changes in their levels in the tumors of AHR +/- CH223191 
treated mice. CCL11 is a chemokine that helps in the mobilization of eosinophils. There 
were no changes in the levels of IL-13, IL-15, VEGF-A, IP10 (CXCL-10) and MIG 
(CXCL9) with increased tumor burden.  
The data herein show a a pro-inflammatory tumor environment with increased IL-
6 levels and a reduced IL-10 and IFN-γ levels with increased tumor burden. A chronic pro-
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inflammatory environment is thought to result in an increase in free radicals, hence DNA 
damage and mutations, leading to tumor initiation and or progression.  
AHR is expressed in the intraepithelial lymphocytes (IELs) and innate lymphoid 
cells (ILCs) along with AHR ligands derived from diet, are essential for maintaining an 
intact gut lining. The lumen of the intestine is comprised of many species of commensal 
bacteria in a symbiotic relationship with its host. The gut’s immune system has a 
challenging role in maintaining a barrier by providing protection to the host and at the same 
time maintaining tolerance towards these beneficial bacteria [12]. Loss of ILC3, IELs, IL-
22 and dysregulation of intestinal bacteria has been observed in the absence of AHR. AHR 
KO mice also have reduced peyer’s patches, compromised gut biota and are prone to 
intestinal infections [63]. As microbiota of the gut plays a crucial role in shaping systemic 
immune responses; manipulating it could be used to modulate cancer immunotherapy [64]. 
The microbiota of MC38 tumor bearing AHR KO and CH223191-treated wild-type mice 
were not evaluated in studies reported herein. Experiments involving modulating of the gut 
microbiota would be interesting to do in the future. 
 
Conclusion: Based on the results described here, AHR plays a crucial role in the MC38 
tumor burden, the absence of which leads to tumor progression by reducing the infiltration 
of cytotoxic T lymphocytes and recruitment of F4/80 + tumor associated macrophages 
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